Lantheus Medical Imaging 10-Q 12 Nov 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Nov. 12, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Entity Registrant Name	'Lantheus Medical Imaging, Inc.	'
Entity Central Index Key	'0001500157	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Non-accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	1,000

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Comprehensive Income (Loss) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Statement of Comprehensive Income [Abstract]	'	'	'	'
Revenues	$75,682	$70,385	$224,631	$212,004
Cost of goods sold	44,044	46,664	131,873	144,524
Gross profit	31,638	23,721	92,758	67,480
Operating expenses	'	'	'	'
Sales and marketing expenses	8,327	8,476	27,227	27,266
General and administrative expenses	8,722	7,132	26,564	25,678
Research and development expenses	3,049	5,893	8,958	25,428
Impairment of land	'	6,788	'	6,788
Total operating expenses	20,098	28,289	62,749	85,160
Operating income (loss)	11,540	-4,568	30,009	-17,680
Interest expense, net	-10,585	-11,035	-31,704	-32,323
Other income (expense), net	441	260	-148	894
Income (loss) before income taxes	1,396	-15,343	-1,843	-49,109
(Benefit) provision for income taxes	-56	-279	-374	267
Net income (loss)	1,452	-15,064	-1,469	-49,376
Foreign currency translation	-671	417	-339	-1,176
Total comprehensive income (loss)	$781	($14,647)	($1,808)	($50,552)

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets	'	'
Cash and cash equivalents	$25,205	$16,669
Accounts receivable, net of allowance of $425 and $290	41,160	38,910
Inventory	16,425	18,310
Income tax receivable	448	325
Deferred tax assets	12	18
Other current assets	4,181	3,087
Total current assets	87,431	77,319
Property, plant and equipment, net	96,072	97,653
Capitalized software development costs, net	1,829	1,470
Intangibles, net	29,203	34,998
Goodwill	15,714	15,714
Deferred financing costs	7,969	9,639
Deferred tax assets	45	15
Other long-term assets	19,791	22,577
Total assets	258,054	259,385
Current liabilities	'	'
Line of credit	8,000	8,000
Accounts payable	15,383	18,103
Accrued expenses and other liabilities	35,088	25,492
Deferred tax liability	57	57
Deferred revenue	1,063	3,979
Total current liabilities	59,591	55,631
Asset retirement obligation	7,244	6,385
Long-term debt, net	399,220	399,037
Deferred tax liability	8	12
Other long-term liabilities	32,407	35,408
Total liabilities	498,470	496,473
Commitments and contingencies (See Note 13)	'	'
Stockholder's deficit	'	'
Common stock ($0.001 par value, 10,000 shares authorized; 1 share issued and outstanding)	'	'
Due from parent	-3,561	-1,259
Additional paid-in capital	3,685	2,903
Accumulated deficit	-239,807	-238,338
Accumulated other comprehensive loss	-733	-394
Total stockholder's deficit	-240,416	-237,088
Total liabilities and stockholder's deficit	$258,054	$259,385

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Statement of Financial Position [Abstract]	'	'
Accounts receivable, allowance	$425	$290
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	10,000	10,000
Common stock, share issued	1	1
Common stock, share outstanding	1	1

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Stockholder's Deficit (USD $)	Total	Common Stock [Member]	Due from Parent [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
In Thousands, except Share data	USD ($)		USD ($)	USD ($)	USD ($)	USD ($)
Balance at Dec. 31, 2012	($174,353)	'	($1,353)	$2,325	($176,660)	$1,335
Balance, (in shares) at Dec. 31, 2012	'	1	'	'	'	'
Net loss	-61,678	'	'	'	-61,678	'
Payments from parent	94	'	94	'	'	'
Foreign currency translation	-1,729	'	'	'	'	-1,729
Stock-based compensation	578	'	'	578	'	'
Balance at Dec. 31, 2013	-237,088	'	-1,259	2,903	-238,338	-394
Balance, (in shares) at Dec. 31, 2013	'	1	'	'	'	'
Net loss	-1,469	'	'	'	-1,469	'
Increase in amounts due from parent	-2,302	'	-2,302	'	'	'
Foreign currency translation	-339	'	'	'	'	-339
Stock-based compensation	782	'	'	782	'	'
Balance at Sep. 30, 2014	($240,416)	'	($3,561)	$3,685	($239,807)	($733)
Balance, (in shares) at Sep. 30, 2014	'	1	'	'	'	'

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities	'	'
Net loss	($1,469)	($49,376)
Adjustments to reconcile net loss to cash flow from operating activities	'	'
Depreciation and amortization	14,808	21,694
Provision for excess and obsolete inventory	1,529	2,488
Impairment of land	'	6,788
Impairment of customer relationship intangible asset	'	1,034
Stock-based compensation	782	735
Deferred income taxes	-30	-315
Other	-72	267
Increase (decrease) in cash from operating assets and liabilities	'	'
Accounts receivable	-2,383	3,864
Inventory	668	-1,871
Other current assets	-1,329	1,443
Accounts payable	-2,971	556
Accrued expenses and other liabilities	8,979	4,660
Income taxes	-123	299
Deferred revenue	-2,941	-4,088
Cash provided by (used in) operating activities	15,448	-11,822
Cash flows from investing activities	'	'
Capital expenditures	-5,303	-3,711
Proceeds from sale of property, plant and equipment	227	'
Redemption of certificate of deposit-restricted	228	'
Cash used in investing activities	-4,848	-3,711
Cash flows from financing activities	'	'
Proceeds from line of credit	5,500	8,000
Payments on line of credit	-5,500	'
Payments on note payable	-52	-1,174
Deferred financing costs	-139	-1,188
Payments (to)/from parent	-1,741	111
Cash (used in) provided by financing activities	-1,932	5,749
Effect of foreign exchange rate on cash	-132	-949
Increase (decrease) in cash and cash equivalents	8,536	-10,733
Cash and cash equivalents, beginning of period	16,669	31,595
Cash and cash equivalents, end of period	25,205	20,862
Supplemental disclosure of cash flow information	'	'
Interest paid	19,692	19,639
Income taxes paid, net	375	-30
Noncash investing and financing activities	'	'
Property, plant and equipment included in accounts payable and accrued expenses and other liabilities	1,488	809
Expenses to be paid on behalf of parent included in accounts payable and accrued expenses and other liabilities	$561	'

Business_Overview

Business Overview	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Business Overview	'
	1. Business Overview
	Overview
	The Company develops, manufactures, sells and distributes innovative diagnostic medical imaging agents and products that assist clinicians in the diagnosis of cardiovascular and other diseases. The Company’s commercial products are used by nuclear physicians, cardiologists, radiologists, internal medicine physicians, technologists and sonographers working in a variety of clinical settings. The Company sells its products to radiopharmacies, hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations and, in certain circumstances, wholesalers. The Company sells its products globally and has operations in the United States, Puerto Rico, Canada and Australia and distribution relationships in Europe, Asia Pacific and Latin America.
	The Company’s portfolio of 10 commercial products is diversified across a range of imaging modalities. The Company’s imaging agents include medical radiopharmaceuticals (including technetium generators) and contrast agents, including the following:
		•	DEFINITY is the leading ultrasound contrast imaging agent used by cardiologists and sonographers during cardiac ultrasound, or echocardiography, exams based on revenue and usage. DEFINITY is an injectable agent that, in the United States, is indicated for use in patients with suboptimal echocardiograms to assist in the visualization of the left ventricle, the main pumping chamber of the heart. The use of DEFINITY in echocardiography allows physicians to significantly improve their assessment of the function of the left ventricle.
		•	TechneLite is a self-contained system, or generator, of technetium (Tc99m), a radioisotope with a six hour half-life, used by radiopharmacies to prepare various nuclear imaging agents.
		•	Xenon Xe 133 Gas is a radiopharmaceutical gas that is inhaled and used to assess pulmonary function and also to image blood flow.
		•	Cardiolite is an injectable, technetium-labeled imaging agent, also known by its generic name sestamibi, used with Single Photon Emission Computed Tomography, or SPECT, technology in myocardial perfusion imaging, or MPI, procedures that assess blood flow distribution to the heart.
		•	Neurolite is an injectable, technetium-labeled imaging agent used with SPECT technology to identify the area within the brain where blood flow has been blocked or reduced due to stroke.
	In the United States, the Company sells DEFINITY through its sales team that calls on healthcare providers in the echocardiography space, as well as group purchasing organizations and integrated delivery networks. The Company’s radiopharmaceutical products are primarily distributed through approximately 350 radiopharmacies owned or controlled by third parties. In Canada, Puerto Rico and Australia, the Company owns nine radiopharmacies and sells its own radiopharmaceuticals, as well as others, directly to end users. In Europe, Asia Pacific and Latin America, the Company utilizes distributor relationships to market, sell and distribute its products.
	Basis of Consolidation and Presentation
	The financial statements have been prepared in United States dollars, in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
	In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of the Company’s financial statements for interim periods in accordance with U.S. GAAP. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the Company’s consolidated financial statements and the accompanying notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013, or the 2013 Form 10-K. The Company’s accounting policies are described in the “Notes to Consolidated Financial Statements” in the 2013 Form 10-K. There were no changes to the Company’s accounting policies since December 31, 2013. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. The results of operations for the three and nine months ended September 30, 2014 are not necessarily indicative of the operating results for the full year or for any other subsequent interim period.
	Recent Events
	The Company incurred a net loss of $1.5 million during the nine months ended September 30, 2014 and had an accumulated deficit of $239.8 million at September 30, 2014. During 2013, the Company relied on Ben Venue Laboratories, Inc., or BVL, as its sole manufacturer of Neurolite and as one of its two manufacturers of DEFINITY and Cardiolite. Following extended operational and regulatory challenges at BVL’s Bedford, Ohio facility, as of November 15, 2013, BVL ceased manufacturing for the Company any DEFINITY, Cardiolite or Neurolite product. BVL has since released for commercial distribution all of the Company’s remaining manufactured product that was awaiting BVL quality approval. The supply challenges with BVL in recent years have had a negative impact on the Company’s results. The Company has taken specific steps to address the supply chain risks and reduce discretionary spend.
	Following extensive technology transfer activities, the Company currently relies on Jubilant HollisterStier, or JHS, as its sole source manufacturer of DEFINITY and evacuation vials for TechneLite. The Company has additional ongoing technology transfer activities at JHS for its Neurolite product supply. In the meantime, the Company has no other currently active supplier of Neurolite, and its Cardiolite product supply is currently manufactured by a single manufacturer.
	The Company is also pursuing new manufacturing relationships to establish and secure additional or alternative suppliers for its commercial products. On November 12, 2013, the Company entered into a Manufacturing and Supply Agreement with Pharmalucence to manufacture and supply DEFINITY. The Company currently believes that Pharmalucence will obtain FDA approval to manufacture DEFINITY in 2015.
	Based on current projections, the Company believes that it will have sufficient supply of DEFINITY from JHS and remaining BVL inventory to meet expected demand and sufficient Cardiolite product supply from its current manufacturer to meet expected demand. The Company also currently anticipates that it will have sufficient BVL-manufactured Neurolite supply for the U.S. market to last until Neurolite technology transfer and U.S. regulatory approval at JHS are completed.
	If JHS is not able to continue to manufacture and release adequate product supply on a timely and consistent basis, the Company is not successful with the remainder of its JHS technology transfer programs and cannot obtain adequate supply from JHS, or the Company is unable to continue to grow DEFINITY sales, then the Company will need to implement additional expense reductions, such as a delay or elimination of discretionary spending in all functional areas as well as in other operating and strategic initiatives.
	During 2013 and 2014, the Company has utilized its line of credit as a source of liquidity from time to time. Borrowing capacity under the revolving credit facility, or the Facility, is calculated by reference to a borrowing base consisting of a percentage of certain eligible accounts receivable, inventory and machinery and equipment minus any reserves, or the Borrowing Base. If the Company is not successful in achieving its forecasted results, the Company’s accounts receivable and inventory could be negatively affected, thus reducing the Borrowing Base and limiting the Company’s borrowing capacity. As of September 30, 2014, the Borrowing Base was approximately $47.5 million, which was reduced by (i) an outstanding $8.8 million unfunded Standby Letter of Credit and (ii) an $8.1 million outstanding loan balance including interest, resulting in a net Borrowing Base availability of approximately $30.6 million.
	The Company took actions during March 2013 to substantially reduce its discretionary spending. In particular, the Company began to implement a strategic shift in how it funds its research and development, or R&D, programs. The Company reduced its internal R&D resources during 2013, while at the same time it sought to engage one or more strategic partners to assist in the further development and commercialization of its agents in development, including flurpiridaz F 18, 18F LMI 1195 and LMI 1174. The Company has completed its 301 trial for flurpiridaz F 18 with internal funding. The Company is seeking to engage strategic partners to assist with the further development and possible commercialization of that agent. For the other two agents in development, 18F LMI 1195 and LMI 1174, the Company is also seeking to engage strategic partners to assist with the ongoing development activities relating to these agents. Based on the Company’s current operating plans, the Company believes its existing cash and cash equivalents, results of operations and availability under the Facility will be sufficient to continue to fund the Company’s liquidity requirements for at least the next twelve months.
	Use of Estimates
	The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. The more significant estimates reflected in the Company’s condensed consolidated financial statements include certain judgments regarding revenue recognition, goodwill, tangible and intangible asset valuation, inventory valuation and potential losses on purchase commitments, asset retirement obligations, income tax liabilities, deferred tax assets and liabilities, accrued expenses and stock-based compensation. Actual results could materially differ from those estimates or assumptions.
	Recent Accounting Standards
	In July 2013, the Financial Accounting Standards Board, or the FASB, issued Accounting Standards Update , or ASU, No. 2013-11, “Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists,” or ASU 2013-11. The amendments in ASU 2013-11 provide guidance on the financial statement presentation of unrecognized tax benefits when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. ASU 2013-11 was effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments did not have a material impact on the Company’s financial position, results of operations or cash flows.
	In April 2014, the FASB issued ASU No. 2014-08, “Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity,” or ASU 2014-08. The amendments in ASU 2014-08 change the criteria for reporting discontinued operations while enhancing disclosures in this area. The new guidance requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations. The new guidance also requires disclosure of the pre-tax income attributable to a disposal of a significant part of an organization that does not qualify for discontinued operations reporting. The amendments in the ASU are effective in the first quarter of 2015 for public companies with calendar year ends. Early adoption is permitted. The Company does not anticipate this ASU will have a material impact to the Company’s financial position, results of operations or cash flows.
	In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)” or ASU 2014-09. ASU 2014-09 supersedes nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing U.S. GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The amendments in ASU No. 2014-09 are effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. The Company is currently evaluating the impact this ASU will have on the Company’s financial position, results of operations and cash flows.
	In June 2014, the FASB issued ASU No. 2014-12, “Compensation – Stock Compensation (Topic 718)” or ASU 2014-12. ASU 2014-12 requires that a performance target that affects vesting and could be achieved after the requisite service period be treated as a performance condition. The amendments in ASU 2014-12 are effective for annual reporting periods beginning after December 15, 2015, including interim periods within that reporting period. The Company does not anticipate this ASU will have a material impact to the Company’s financial position, results of operations or cash flows.
	In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements-Going Concern (Subtopic 205-4): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” or ASU 2014-15. ASU 2014-15 to provide guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and to provide related footnote disclosures. The amendments in ASU 2014-15 are effective for annual reporting periods ending after December 15, 2016. Early adoption is permitted. The Company does not anticipate this ASU will have a material impact to the Company’s financial position, results of operations or cash flows.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	2. Summary of Significant Accounting Policies
	Revenue Recognition
	The Company recognizes revenue when evidence of an arrangement exists, title has passed, the risks and rewards of ownership have transferred to the customer, the selling price is fixed or determinable, and collectability is reasonably assured. For transactions for which revenue recognition criteria have not yet been met, the respective amounts are recorded as deferred revenue until such point in time the criteria are met and revenue can be recognized. Revenue is recognized net of reserves, which consist of allowances for returns and rebates.
	Revenue arrangements with multiple elements are divided into separate units of accounting if certain criteria are met, including whether the delivered element has stand-alone value to the customer. The arrangement’s consideration is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective evidence of fair value; (ii) third-party evidence of selling price; and (iii) best estimate of selling price. The best estimate of selling price reflects the Company’s best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis. The consideration allocated to each unit of accounting is then recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. Supply or service transactions may involve the charge of a nonrefundable initial fee with subsequent periodic payments for future products or services. The up-front fees, even if nonrefundable, are recognized as revenue as the products and/or services are delivered and performed over the term of the arrangement.
	Inventory
	Inventory costs associated with product that has not yet received regulatory approval are capitalized if the Company believes there is probable future commercial use of the product and future economic benefits of the asset. If future commercial use of the product is not probable, then inventory costs associated with such product are expensed during the period the costs are incurred. For the nine months ended September 30, 2014, the Company expensed $1.7 million of such product costs in cost of goods sold relating to Neurolite that was manufactured by JHS. At September 30, 2014 and December 31, 2013, the Company had no capitalized inventories associated with product that did not have regulatory approval.
	Goodwill
	Goodwill is not amortized, but is instead tested for impairment at least annually and whenever events or circumstances indicate that it is more likely than not that it may be impaired. The Company has elected to perform the annual test for goodwill impairment as of October 31 of each year. All goodwill has been allocated to the U.S. operating segment.
	During the first quarter of 2013, the strategic shift in how the Company funds its R&D programs significantly altered the expected future costs and revenues associated with the Company’s agents in development. Accordingly, this action was deemed to be a triggering event for an evaluation of the recoverability of the Company’s goodwill as of March 31, 2013. The Company performed an interim impairment test and determined that there was no goodwill impairment as of March 31, 2013. There were no events as of September 30, 2014 and December 31, 2013 that triggered an interim impairment test of goodwill.
	The Company calculates the fair value of its reporting units using the income approach, which utilizes discounted forecasted future cash flows and the market approach which utilizes fair value multiples of comparable publicly traded companies. The discounted cash flows are based on the Company’s most recent long-term financial projections and are discounted using a risk adjusted rate of return, which is determined using estimates of market participant risk-adjusted weighted average costs of capital and reflects the risks associated with achieving future cash flows. The market approach is calculated using the guideline company method, where the Company uses market multiples derived from stock prices of companies engaged in the same or similar lines of business. A combination of the two methods is utilized to derive the fair value of the business in order to decrease the inherent risk associated with each model if used independently.

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value of Financial Instruments	'
	3. Fair Value of Financial Instruments
	The tables below present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2014 and December 31, 2013, and indicate the fair value hierarchy of the valuation techniques utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize data points from active markets that are observable, such as quoted prices, interest rates and yield curves. Fair values determined by Level 3 inputs utilize unobservable data points for the asset or liability.
	September 30, 2014	Total fair		Quoted prices		Significant other		Significant
		value		in active		observable		unobservable
	(in thousands)			markets		inputs		inputs
				(Level 1)		(Level 2)		(Level 3)
	Money market	$	2,192	$	2,192	$	—	$	—
	Certificate of deposit—restricted		93		—		93		—
	Total	$	2,285	$	2,192	$	93	$	—
	December 31, 2013	Total fair		Quoted prices		Significant other		Significant
		value		in active		observable		unobservable
	(in thousands)			markets		inputs		inputs
				(Level 1)		(Level 2)		(Level 3)
	Money market	$	1,236	$	1,236	$	—	$	—
	Certificates of deposit—restricted		322		—		322		—
	Total	$	1,558	$	1,236	$	322	$	—
	At December 31, 2013, the Company had a $0.2 million certificate of deposit for which the Company’s use of such cash was restricted and is included in the line item “Certificates of deposit—restricted” above. This investment was classified in other current assets on the condensed consolidated balance sheet and was redeemed during the quarter ended September 30, 2014. The remaining $0.1 million at both September 30, 2014 and December 31, 2013, represents a certificate of deposit that is collateral for a long-term lease and is included in other long-term assets on the condensed consolidated balance sheet. Certificates of deposit are classified within Level 2 of the fair value hierarchy, as these are not traded on the open market.
	At September 30, 2014, the Company had total cash and cash equivalents of $25.2 million, which included approximately $2.2 million of money market funds and $23.0 million of cash on-hand. At December 31, 2013, the Company had total cash and cash equivalents of $16.7 million, which included approximately $1.2 million of money market funds and $15.5 million of cash on-hand.
	The estimated fair values of the Company’s financial instruments, including its cash and cash equivalents, receivables, line of credit, accounts payable and accrued expenses approximate the carrying values of these instruments due to their short term nature. The estimated fair value of the debt at September 30, 2014, based on Level 2 inputs of recent market activity available to the Company, was $392.0 million compared to the face value of $400.0 million. At December 31, 2013, the estimated fair value of the debt was $356.0 million compared to the face value of $400.0 million.

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	4. Income Taxes
	The Company provides for income taxes at the end of each interim period based on the estimated effective tax rate for the full fiscal year in addition to discrete events which impact the interim period. The Company’s effective tax rate differs from the U.S. statutory rate principally due to the rate impact of uncertain tax positions, valuation allowance changes and state taxes. Cumulative adjustments to the tax provision are recorded in the interim period in which a change in the estimated annual effective rate is determined. The Company’s tax benefit was $0.1 million and $0.4 million for the three and nine months ended September 30, 2014, respectively, compared to a tax benefit of $0.3 million and a provision of $0.3 million for the three and nine months ended September 30, 2013, respectively.
	In connection with the Company’s acquisition of the medical imaging business from Bristol-Myers Squibb Company, or BMS, in 2008, the Company obtained a tax indemnification agreement from BMS related to certain tax obligations arising prior to the acquisition of the Company, for which the Company has the primary legal obligation. The tax indemnification receivable is recognized within other long-term assets. The changes in the tax indemnification asset are recognized within other income in the condensed consolidated statement of comprehensive income (loss). In accordance with the Company’s accounting policy, the change in the tax liability and penalties and interest associated with these obligations (net of any offsetting federal or state benefit) is recognized within the tax provision. Accordingly, as these reserves change, adjustments are included in the tax provision while the offsetting adjustment is included in other (expense) income. Assuming that the receivable from BMS continues to be considered recoverable by the Company, there is no net effect on earnings related to these liabilities and no net cash outflows.
	On March 13, 2014, New York State, BMS, the Company and a relator entered into a Stipulation and Settlement Agreement and other related agreements, or collectively the Settlement Documents, to resolve an investigation by the Office of the Attorney General of New York State, claims relating to certain New York State and New York City tax matters and related claims under the New York False Claims Act. The claims at issue arose during the period from January 1, 2002 through December 31, 2006, which predated the acquisition of the medical imaging business from BMS in January 2008 and are subject to the tax indemnification agreement described above. Pursuant to the Settlement Documents, BMS paid (on behalf of itself and the Company) $6.3 million, and neither BMS nor the Company admitted any liability. The Company received a full release from New York State, New York City and the relator with respect to the claims at issue.
	The statute of limitations for the year ended December 31, 2010 U.S. tax return expired during the period ended September 30, 2014. The Company recognized the benefit associated with the reversal of uncertain tax positions of $0.9 million and $2.7 million in the three and nine months ended September 30, 2014, respectively. The statute of limitations for the year ended December 31, 2009 U.S. tax return expired during the period ended September 30, 2013. As a result the Company recognized the benefit associated with the reversal of uncertain tax positions of $0.8 million in the three and nine months ended September 30, 2013. Within the next twelve months, approximately $0.4 million of unrecognized tax benefits, primarily relating to transfer pricing, may be recognized due to the closing of statutes of limitation.

Inventory

Inventory	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
Inventory	'
	5. Inventory
	The Company includes within current assets the amount of inventory that is estimated to be utilized within twelve months. Inventory that will be utilized after twelve months is classified within other long-term assets.
	Inventory, classified in inventory or other long-term assets, consisted of the following:
	(in thousands)	September 30,		December 31,
		2014		2013
	Raw materials	$	5,713	$	7,063
	Work in process		4,410		5,849
	Finished goods		6,302		5,398
	Inventory		16,425		18,310
	Other long-term assets		1,406		1,687
	Total	$	17,831	$	19,997
	At September 30, 2014, inventories reported as other long-term assets included $1.2 million of raw materials and $0.2 million of finished goods. At December 31, 2013, inventories reported as other long-term assets included $1.7 million of raw materials.

Property_Plant_and_Equipment_n

Property, Plant and Equipment, net	9 Months Ended
	Sep. 30, 2014
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment, net	'
	6. Property, Plant and Equipment, net
	Property, plant and equipment consisted of the following:
	(in thousands)	September 30,			December 31,
		2014			2013
	Land	$	14,950		$	14,950
	Buildings		67,470			65,787
	Machinery, equipment and fixtures		65,556			65,026
	Construction in progress		7,438			8,029
	Accumulated depreciation		(59,342	)		(56,139	)
	Property, plant and equipment, net	$	96,072		$	97,653
	For the three and nine months ended September 30, 2014, depreciation expense related to property, plant and equipment was $2.2 million and $6.5 million, respectively, as compared to $2.3 million and $7.1 million for the prior year comparative periods.
	Included within machinery, equipment and fixtures are spare parts of approximately $2.5 million at both September 30, 2014 and December 31, 2013. Spare parts include replacement parts relating to plant and equipment and are either recognized as an expense when consumed or re-classified and capitalized as part of the related plant and equipment and depreciated over a time period not exceeding the useful life of the related asset.
	Fixed assets dedicated to R&D activities, which were impacted by the March 2013 R&D strategic shift, have a carrying value of $5.2 million as of September 30, 2014. The Company believes these fixed assets will be utilized for either internally funded ongoing R&D activities or R&D activities funded by a strategic partner. If the Company is not successful in finding a strategic partner and there are no alternative uses for these fixed assets, then they could be subject to impairment in the future.
	Long-Lived Assets Held for Sale
	During the third quarter of 2013, the Company committed to a plan to sell certain of its excess land in the U.S. segment. This event qualified for held for sale accounting and the excess land was written down to its fair value, less estimated costs to sell. This resulted in a loss of $6.8 million, which is included within operating loss as impairment of land in the accompanying condensed consolidated statement of comprehensive income (loss). The fair value was estimated utilizing Level 3 inputs and using a market approach, based on available data for transactions in the region, discussions with real estate brokers and the asking price of comparable properties in its principal market. During the fourth quarter of 2013, the Company sold the excess land for net proceeds of $1.1 million.

Asset_Retirement_Obligations

Asset Retirement Obligations	9 Months Ended
	Sep. 30, 2014
Asset Retirement Obligation Disclosure [Abstract]	'
Asset Retirement Obligations	'
	7. Asset Retirement Obligations
	The Company considers the legal obligation to remediate its facilities upon a decommissioning of its radioactive related operations as an asset retirement obligation. The operations of the Company have radioactive production facilities at its North Billerica, Massachusetts and San Juan, Puerto Rico sites.
	The Company is required to provide the U.S. Nuclear Regulatory Commission and Massachusetts Department of Public Health financial assurance demonstrating the Company’s ability to fund the decommissioning of the North Billerica, Massachusetts production facility upon closure, although the Company does not intend to close the facility. The Company has provided this financial assurance in the form of a $28.2 million surety bond, which itself is currently secured by an $8.8 million unfunded Standby Letter of Credit provided to the third party issuer of the bond.
	The fair value of a liability for asset retirement obligations is recognized in the period in which the liability is incurred. As of September 30, 2014, the liability is measured at the present value of the obligation expected to be incurred, of approximately $26.6 million, and is adjusted in subsequent periods as accretion expense is recorded. The corresponding asset retirement costs are capitalized as part of the carrying value of the related long-lived assets and depreciated over the asset’s useful life.
	The following is a reconciliation of the Company’s asset retirement obligations for the nine months ended September 30, 2014:
	(in thousands)
	Balance at January 1, 2014	$	6,385
	Capitalization		277
	Accretion expense		582
	Balance at September 30, 2014	$	7,244

Intangibles_net

Intangibles, net	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Intangibles, net	'
	8. Intangibles, net
	Intangibles, net consisted of the following:
		September 30, 2014
	(in thousands)	Cost		Accumulated		Net		Amortization
				amortization				Method
	Trademarks	$	13,540	$	4,662	$	8,878	Straight-line
	Customer relationships		105,942		88,094		17,848	Accelerated
	Other patents		42,780		40,303		2,477	Straight-line
		$	162,262	$	133,059	$	29,203
		December 31, 2013
	(in thousands)	Cost		Accumulated		Net		Amortization
				amortization				Method
	Trademarks	$	13,540	$	3,298	$	10,242	Straight-line
	Customer relationships		106,298		84,476		21,822	Accelerated
	Other patents		42,780		39,846		2,934	Straight-line
		$	162,618	$	127,620	$	34,998
	During the third quarter of 2013, the Company was in negotiations with a new distributor for the sale of certain products within certain international geographies. This agreement was signed in October 2013 and the Company did not renew the agreements with its former distributors in these international geographies. Therefore, the Company reviewed the recoverability of certain of its customer relationship intangible assets in the International segment. The Company completed an update of its sales forecast based on current negotiations with new customers and its impact on its existing customer base. The Company, using its revised sales forecast, conducted an impairment analysis and concluded that the estimate of future undiscounted cash flows associated with the acquired customer relationships did not exceed the carrying amount of the asset and therefore, the asset would need to be written down to its fair value. In order to calculate the fair value of the acquired customer relationship intangible assets, the Company utilized Level 3 inputs to estimate the future discounted cash flows associated with remaining customers and as a result of this analysis, recorded an impairment charge of $1.0 million to adjust the carrying value to its fair value. This expense was recorded within cost of goods sold in the accompanying condensed consolidated statement of comprehensive income (loss) for the three and nine months ended September 30, 2013.
	For the three and nine months ended September 30, 2014, the Company recorded amortization expense for its intangible assets of $1.9 million and $5.7 million, respectively, as compared to $3.6 million and $10.8 million for the prior year comparative periods.
	Expected future amortization expense related to the intangible assets is as follows:
	(in thousands)
	Remainder of 2014	$	1,902
	2015		6,021
	2016		5,337
	2017		3,521
	2018		2,792
	2019 and thereafter		9,630
		$	29,203

Accrued_Expenses_and_Other_Lia

Accrued Expenses and Other Liabilities	9 Months Ended
	Sep. 30, 2014
Text Block [Abstract]	'
Accrued Expenses and Other Liabilities	'
	9. Accrued Expenses and Other Liabilities
	Accrued expenses and other liabilities are comprised of the following:
	(in thousands)	September 30,		December 31,
		2014		2013
	Compensation and benefits	$	10,875	$	10,209
	Accrued interest		14,719		4,989
	Accrued professional fees		1,713		1,361
	Research and development services		220		338
	Freight, distribution and operations		3,187		3,432
	Accrued loss on firm purchase commitment		—		1,315
	Marketing expense		1,243		749
	Accrued rebates, discounts and chargebacks		2,729		1,739
	Other		402		1,360
		$	35,088	$	25,492
	As of December 31, 2013, the Company had accrued a contract loss of $1.3 million associated with the portion of the committed purchases of Ablavar product from the Company’s supplier that the Company did not believe it would sell prior to expiry. As of September 30, 2014, the accrued contract loss has been reclassified to a reserve against the Ablavar inventory balance, because the Company satisfied the remaining purchase commitments in the first quarter of 2014.

Financing_Arrangements

Financing Arrangements	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Financing Arrangements	'
	10. Financing Arrangements
	Senior Notes
	LMI has $400.0 million in aggregate principal amount of Senior Notes, or the Notes, outstanding. The Notes bear interest at a rate of 9.750% per year, payable on May 15 and November 15 of each year. The Notes mature on May 15, 2017.
	Revolving Line of Credit
	LMI had a Facility with an original aggregate principal amount not to exceed $42.5 million. On June 24, 2014, the Company executed an amendment to the Facility, which (i) increased the committed availability for total borrowings under the Facility from $42.5 million to $50.0 million, (ii) set the interest at LIBOR plus 2.00% or the Reference Rate (as defined in the agreement) plus 1.00%, (iii) set the unused line fee at 0.375%, and (iv) further modified certain definitions. In connection with the amendment, LMI incurred approximately $0.2 million in fees and expenses as of September 30, 2014, which will be amortized on a straight-line basis over the term of the Facility.
	The Facility expires on the earlier of (i) July 3, 2018, or (ii) if the outstanding Notes are not refinanced in full, the date that is 91 days before the maturity thereof, at which time all outstanding borrowings are due and payable.
	As of September 30, 2014 and December 31, 2013, the Company has an unfunded Standby Letter of Credit for up to $8.8 million. The unfunded Standby Letter of Credit requires an annual fee, payable quarterly, which is set at LIBOR plus a spread of 2.00% and expires on February 5, 2015, which will automatically renew for a one year period at each anniversary date, unless the Company elects not to renew in writing within 60 days prior to that expiration.
	The Facility is secured by a pledge of substantially all of the assets of each of the Company, LMI and Lantheus Real Estate, including each entity’s accounts receivable, inventory and machinery and equipment, and is guaranteed by each of Lantheus Intermediate and Lantheus Real Estate. Borrowing capacity is determined by reference to a Borrowing Base, which is based on a percentage of certain eligible accounts receivable, inventory and machinery and equipment minus any reserves. As of September 30, 2014, the aggregate Borrowing Base was approximately $47.5 million, which was reduced by (i) an outstanding $8.8 million unfunded Standby Letter of Credit and (ii) an $8.1 million outstanding loan balance including interest, resulting in a net Borrowing Base availability of approximately $30.6 million.

StockBased_Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock-Based Compensation	'
	11. Stock-Based Compensation
	The Company’s employees are eligible to receive awards under the Holdings 2013 Equity Incentive Plan, or the 2013 Plan. The 2013 Plan is administered by the Holdings Board of Directors and permits the granting of nonqualified stock options, stock appreciation rights, or SARs, restricted stock and restricted stock units to employees, officers, directors and consultants of Holdings or any subsidiary of Holdings (including Lantheus Intermediate and LMI). On August 5, 2013, the Holdings Board of Directors adopted a resolution providing that no further grants be made under the Holdings 2008 Equity Incentive Plan, or the 2008 Plan. At the same time, the maximum number of shares that may be issued pursuant to awards under the 2013 Plan was increased from 1,500,000 to 2,700,000. Option awards under the 2013 Plan are granted with an exercise price equal to the fair value of Holdings’ stock at the date of grant, as determined by the Board of Directors of Holdings. Time based option awards vest based on time, either four or five years, and performance based option awards vest based on the performance criteria specified in the grant. All option awards have a ten-year contractual term. The Company recognizes compensation costs for its time based awards on a straight-line basis equal to the vesting period. The compensation cost for performance based awards is recognized on a graded vesting basis, based on the probability of achieving the performance targets over the requisite service period for the entire award. The fair value of each option award is estimated on the date of grant using a Black-Scholes valuation model that uses the assumptions noted in the following table. Expected volatilities are based on the historic volatility of a selected peer group. Expected dividends represent the dividends expected to be issued at the date of grant. The expected term of options represents the period of time that options granted are expected to be outstanding. The risk-free interest rate assumption is the U.S. Treasury rate at the date of the grant which most closely resembles the expected life of the options.
	The Company uses the following Black-Scholes inputs to determine the fair value of new stock option grants.
		Three Months						Nine Months
		Ended September 30,						Ended September 30,
		2014			2013			2014		2013
	Expected volatility		—			36	%	33 - 35%		36%
	Expected dividends		—			—		—		—
	Expected life (in years)		—			6.3		5.5 - 6.3		5.5 - 6.3
	Risk-free interest rate		—			1.7	%	1.5 – 1.9%		0.7 - 1.7%
	A summary of option activity for 2014 is presented below:
		Time Based			Performance			Total			Weighted		Weighted		Aggregate
					Based						Average		Average		Intrinsic
											Exercise		Remaining		Value
											Price		Contractual
													Term
	Outstanding at January 1, 2014		2,761,037			1,097,425			3,858,462		$	4.89		6.9	$	6,777,000
	Options granted		74,664			—			74,664			5.98
	Options cancelled		(21,500	)		(6,952	)		(28,452	)		4.88
	Options exercised		(4,500	)		(1,737	)		(6,237	)		2
	Options forfeited or expired		(31,000	)		(7,880	)		(38,880	)		7.29
	Outstanding at September 30, 2014		2,778,701			1,080,856			3,859,557			4.89		6.2	$	3,979,000
	Vested and expected to vest at September 30, 2014		2,715,687			701,755			3,417,442			4.64		5.9	$	3,979,000
	Exercisable at September 30, 2014		1,815,393			548,302			2,363,695			3.58		4.7	$	3,979,000
	The weighted average grant-date fair value of options granted during the nine months ended September 30, 2014 was $2.08. No options were granted during the three months ended September 30, 2014. The weighted average grant-date fair value of options granted during the three and nine months ended September 30, 2013 was $2.53 and $2.45, respectively.
	Stock-based compensation expense for both time based and performance based awards was recognized in the condensed consolidated statements of comprehensive income (loss) as follows:
		Three Months						Nine Months
		Ended						Ended
		September 30,						September 30,
	(in thousands)	2014			2013			2014			2013
	Cost of goods sold	$	32		$	26		$	104		$	56
	Sales and marketing		34			46			116			86
	General and administrative		151			62			474			553
	Research and development		30			38			88			40
	Total stock-based compensation expense	$	247		$	172		$	782		$	735
	Stock-based compensation expense recognized in the condensed consolidated statement of comprehensive income (loss) for the three and nine months ended September 30, 2014 and 2013 are based on awards ultimately expected to vest as well as any changes in the probability of achieving certain performance features as required.
	Upon termination of employment, Holdings has the right to call shares held by employees that were purchased or acquired through option exercise. As a result of this right, upon termination of service, vested stock-based awards are reclassified to liability-based awards when it is probable the employee will exercise the option and that Holdings will exercise its call right. As of September 30, 2014 and December 31, 2013, the Company did not have any liability-based awards outstanding.
	The Company did not recognize an income tax benefit with respect to stock compensation in either the nine months ended September 30, 2014 or 2013. As of September 30, 2014, there was approximately $2.1 million of total unrecognized compensation costs related to non-vested stock options granted under the 2013 and 2008 Plans. These costs are expected to be recognized over a weighted-average remaining period of 1.3 years. In addition, performance based awards contain certain contingent features, such as change in control provisions, which allow for the vesting of previously forfeited and unvested awards. As of September 30, 2014, there was approximately $1.0 million of unrecognized compensation expense relating to these features, which could be recognized through 2023.

Other_Expense_Income_net

Other (Expense) Income, net	9 Months Ended
	Sep. 30, 2014
Other Income and Expenses [Abstract]	'
Other (Expense) Income, net	'
	12. Other (Expense) Income, net
	Other (expense) income, net consisted of the following:
		Three Months					Nine Months
		Ended					Ended
		September 30,					September 30,
	(in thousands)	2014		2013			2014			2013
	Foreign currency (losses) gains	$	82	$	(174	)	$	(311	)	$	(180	)
	Tax indemnification income		359		434			163			706
	Other income		—		—			—			368
	Total other income (expense), net	$	441	$	260		$	(148	)	$	894

Legal_Proceedings_and_Continge

Legal Proceedings and Contingencies	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Legal Proceedings and Contingencies	'
	13. Legal Proceedings and Contingencies
	From time to time, the Company is a party to various legal proceedings arising in the ordinary course of business. In addition, the Company has in the past been, and may in the future be, subject to investigations by governmental and regulatory authorities, which expose it to greater risks associated with litigation, regulatory or other proceedings, as a result of which the Company could be required to pay significant fines or penalties. The outcome of litigation, regulatory or other proceedings cannot be predicted with certainty, and some lawsuits, claims, actions or proceedings may be disposed of unfavorably to the Company. In addition, intellectual property disputes often have a risk of injunctive relief which, if imposed against the Company, could materially and adversely affect its financial condition or results of operations. As of September 30, 2014, the Company had no material ongoing litigation in which the Company was a defendant or any material ongoing regulatory or other proceedings and had no knowledge of any investigations by government or regulatory authorities in which the Company is a target that could have a material adverse effect on its current business.
	On December 16, 2010, LMI filed suit against one of its insurance carriers seeking to recover business interruption losses associated with the NRU reactor shutdown and the ensuing global Moly supply shortage. The claim is the result of the shutdown of the NRU reactor in Chalk River, Ontario. The NRU reactor was off-line from May 2009 until August 2010. The defendant answered the complaint on January 21, 2011, denying substantially all of the allegations, presenting certain defenses and requesting dismissal of the case with costs and disbursements. Discovery, including international discovery and related motion practice, has been on-going for more than three years. The defendant filed a motion for summary judgment on July 14, 2014. The Company filed a memorandum of law in opposition to defendant’s motion for summary judgment on August 25, 2014. The defendant filed a reply memorandum of law in further support of its motion for summary judgment on September 15, 2014. Expert witness discovery was completed on October 31, 2014. The Company cannot be certain what amount, if any, or when, if ever, it will be able to recover for business interruption losses related to this matter.

Related_Party_Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions	'
	14. Related Party Transactions
	At September 30, 2014 and December 31, 2013, LMI had outstanding receivables from Holdings in the amount of $3.6 million and $1.3 million, respectively, which was included in due from parent within stockholder’s deficit.
	Avista, the majority shareholder of Holdings, provides certain advisory services to the Company pursuant to an advisory services and monitoring agreement. The Company is required to pay an annual fee of $1.0 million and other reasonable and customary advisory fees, as applicable, paid on a quarterly basis. The initial term of the agreement is seven years. Upon termination, which is at the Company’s option, all remaining amounts owed under the agreement shall become due immediately. During each of the three and nine months ended September 30, 2014, the Company incurred costs associated with this agreement totaling $0.3 million and $0.8 million, respectively, as compared to $0.3 million and $0.8 million for the prior year comparative periods. At September 30, 2014 and December 31, 2013, $16,000 and $30,000, respectively, was included in accrued expenses.
	The Company had a Master Contract Research Organization Services Agreement with INC Research, LLC, or INC, to provide clinical development services in connection with the flurpiridaz F 18 Phase III program. Avista and certain of its affiliates are principal owners of both INC and the Company. The agreement was cancelled during May 2014. The agreement had a term of five years, and the Company did not incur any costs associated with this agreement in the three and nine months ended September 30, 2014. The Company incurred costs associated with this agreement totaling $0.5 million in the nine months ended September 30, 2013. No costs were incurred in the three months ended September 30, 2013. At both September 30, 2014 and December 31, 2013, there was no balance due to INC.
	The Company purchases inventory supplies from VWR Scientific, or VWR. Avista and certain of its affiliates are principal owners of both VWR and the Company. During each of the three and nine months ended September 30, 2014, the Company made purchases of $0.1 million and $0.2 million, respectively, as compared to $0.1 million and $0.2 million for the prior year comparative periods. At September 30, 2014 and December 31, 2013, $20,000 and $1,000, respectively, was included in accounts payable and accrued expenses.
	The Company retains Marsh for insurance brokering and risk management. In November 2013, Donald Bailey, brother of the Company’s President and Chief Executive Officer, Jeffrey Bailey, was appointed head of sales for Marsh’s U.S. and Canada division. In 2014, the Company expects to pay Marsh approximately $0.3 million. At both September 30, 2014 and December 31, 2013, there was a prepaid of $43,000 included in other current assets.
	At December 31, 2013, the Company had $0.1 million due from an officer of the Company included in accounts receivable, net. These amounts represent federal and state tax withholdings paid by the Company on behalf of the officer. During the second quarter of 2014, this amount was fully repaid by the officer.

Segment_Information

Segment Information	9 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
Segment Information	'
	15. Segment Information
	The Company reports two operating segments, U.S. and International, based on geographic customer base. The results of these operating segments are regularly reviewed by our chief operating decision maker, the President and Chief Executive Officer. The Company’s segments derive revenues through the manufacturing, marketing, selling and distribution of medical imaging products, focused primarily on cardiovascular diagnostic imaging. The U.S. segment comprises 78.5% and 77.8% of consolidated revenues for the three and nine months ended September 30, 2014, respectively, as compared to 73.9% and 74.8% for the prior year comparative periods and 90.1% and 89.8% of consolidated assets at September 30, 2014 and December 31, 2013, respectively. All goodwill has been allocated to the U.S. operating segment.
	Selected information for each business segment is as follows (in thousands):
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2014			2013			2014			2013
	Revenues
	U.S.	$	64,311		$	56,407		$	188,679		$	174,167
	International		16,253			18,381			49,823			53,514
	Total revenue, including inter-segment		80,564			74,788			238,502			227,681
	Less inter-segment revenue		(4,882	)		(4,403	)		(13,871	)		(15,677	)
		$	75,682		$	70,385		$	224,631		$	212,004
	Revenues from external customers
	U.S.	$	59,429		$	52,004		$	174,808		$	158,490
	International		16,253			18,381			49,823			53,514
		$	75,682		$	70,385		$	224,631		$	212,004
	Operating income (loss)
	U.S.	$	10,493		$	(5,116	)	$	25,930		$	(18,414	)
	International		1,009			(54	)		3,653			913
	Total operating income (loss), including inter-segment		11,502			(5,170	)		29,583			(17,501	)
	Inter-segment operating income (loss)		38			602			426			(179	)
	Operating income (loss)		11,540			(4,568	)		30,009			(17,680	)
	Interest expense, net		(10,585	)		(11,035	)		(31,704	)		(32,323	)
	Other income (expense), net		441			260			(148	)		894
	Income (loss) before income taxes	$	1,396		$	(15,343	)	$	(1,843	)	$	(49,109	)
		September 30,			December 31,
		2014			2013
	Total Assets
	U.S.	$	232,491		$	232,973
	International		25,563			26,412
		$	258,054		$	259,385

Guarantor_Financial_Informatio

Guarantor Financial Information	9 Months Ended
	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Guarantor Financial Information	'
	16. Guarantor Financial Information
	The Notes, issued by LMI, are guaranteed by Lantheus Intermediate, or the Parent Guarantor, and Lantheus Real Estate, one of Lantheus Intermediate’s wholly-owned consolidated subsidiaries, or the Guarantor Subsidiary. The guarantees are full and unconditional and joint and several. The following supplemental financial information sets forth, on a condensed consolidating basis, balance sheet information as of September 30, 2014 and December 31, 2013, comprehensive income (loss) information for the three and nine months ended September 30, 2014 and 2013 and cash flow information for the nine months ended September 30, 2014 and 2013 for Lantheus Intermediate, LMI, the Guarantor Subsidiary and Lantheus Intermediate’s other wholly-owned subsidiaries, or the Non-Guarantor Subsidiaries. The condensed consolidating financial statements have been prepared on the same basis as the condensed consolidated financial statements of Lantheus Intermediate. The equity method of accounting is followed within this financial information.
	Condensed Consolidating Balance Sheet Information
	September 30, 2014
	(in thousands)	Lantheus			LMI			Guarantor			Non-			Eliminations			Total
		Intermediate						Subsidiary			Guarantor
											Subsidiaries
	Assets:
	Current assets
	Cash and cash equivalents	$	—		$	20,121		$	—		$	5,084		$	—		$	25,205
	Accounts receivable, net		—			30,611			—			10,549			—			41,160
	Intercompany accounts receivable		—			2,962			—			—			(2,962	)		—
	Inventory		—			13,500			—			2,925			—			16,425
	Income tax receivable		—			423			—			25			—			448
	Deferred tax assets		—			—			—			12			—			12
	Other current assets		—			3,916			—			265			—			4,181
	Total current assets		—			71,533			—			18,860			(2,962	)		87,431
	Property, plant and equipment, net		—			75,510			15,555			5,007			—			96,072
	Capitalized software development costs, net		—			1,828			—			1			—			1,829
	Intangibles, net		—			26,628			—			2,575			—			29,203
	Goodwill		—			15,714			—			—			—			15,714
	Deferred financing costs		—			7,969			—			—			—			7,969
	Deferred tax assets		—			—			—			45			—			45
	Investment in subsidiaries		(240,416	)		39,293			—			—			201,123			—
	Intercompany note receivable		—			—			—			5,568			(5,568	)		—
	Other long-term assets		—			19,591			—			200			—			19,791
	Total assets	$	(240,416	)	$	258,066		$	15,555		$	32,256		$	192,593		$	258,054
	Liabilities and (deficit) equity:
	Current liabilities
	Line of credit	$	—		$	8,000		$	—		$	—		$	—		$	8,000
	Accounts payable		—			13,810			—			1,573			—			15,383
	Intercompany accounts payable		—			—			—			2,962			(2,962	)		—
	Accrued expenses and other liabilities		—			31,944			—			3,144			—			35,088
	Deferred tax liability		—			—			—			57			—			57
	Deferred revenue		—			1,063			—			—			—			1,063
	Total current liabilities		—			54,817			—			7,736			(2,962	)		59,591
	Asset retirement obligations		—			7,049			—			195			—			7,244
	Long-term debt, net		—			399,220			—			—			—			399,220
	Intercompany note payable		—			5,568			—			—			(5,568	)		—
	Deferred tax liability		—			—			—			8			—			8
	Other long-term liabilities		—			31,828			—			579			—			32,407
	Total liabilities		—			498,482			—			8,518			(8,530	)		498,470
	(Deficit) equity		(240,416	)		(240,416	)		15,555			23,738			201,123			(240,416	)
	Total liabilities and (deficit) equity	$	(240,416	)	$	258,066		$	15,555		$	32,256		$	192,593		$	258,054
	Condensed Consolidating Balance Sheet Information
	December 31, 2013
	(in thousands)	Lantheus			LMI			Guarantor			Non-			Eliminations			Total
		Intermediate						Subsidiary			Guarantor
											Subsidiaries
	Assets:
	Current assets
	Cash and cash equivalents	$	—		$	11,995		$	—		$	4,674		$	—		$	16,669
	Accounts receivable, net		—			28,099			—			10,811			—			38,910
	Intercompany accounts receivable		—			2,671			—			—			(2,671	)		—
	Inventory		—			15,414			—			2,896			—			18,310
	Income tax receivable		—			297			—			28			—			325
	Deferred tax assets		—			—			—			18			—			18
	Other current assets		—			2,906			—			181			—			3,087
	Total current assets		—			61,382			—			18,608			(2,671	)		77,319
	Property, plant and equipment, net		—			76,068			15,615			5,970			—			97,653
	Capitalized software development costs, net		—			1,468			—			2			—			1,470
	Intangibles, net		—			31,838			—			3,160			—			34,998
	Goodwill		—			15,714			—			—			—			15,714
Deferred financing costs		—			9,639			—			—			—			9,639
Deferred tax assets		—			—			—			15			—			15
Investment in subsidiaries		(237,088	)		40,289			—			—			196,799			—
Intercompany note receivable		—			—			—			5,396			(5,396	)		—
Other long-term assets		—			22,370			—			207			—			22,577
Total assets	$	(237,088	)	$	258,768		$	15,615		$	33,358		$	188,732		$	259,385
Liabilities and (deficit) equity:
Current liabilities
Line of credit	$	—		$	8,000		$	—		$	—		$	—		$	8,000
Accounts payable		—			16,672			—			1,431			—			18,103
Intercompany accounts payable		—			—			—			2,671			(2,671	)		—
Accrued expenses and other liabilities		—			21,409			—			4,083			—			25,492
Deferred tax liability		—			—			—			57			—			57
Deferred revenue		—			3,979			—			—			—			3,979
Total current liabilities		—			50,060			—			8,242			(2,671	)		55,631
Asset retirement obligations		—			6,212			—			173			—			6,385
Long-term debt, net		—			399,037			—			—			—			399,037
Intercompany note payable		—			5,396			—			—			(5,396	)		—
Deferred tax liability		—			—			—			12			—			12
Other long-term liabilities		—			35,151			—			257			—			35,408
Total liabilities		—			495,856			—			8,684			(8,067	)		496,473
(Deficit) equity		(237,088	)		(237,088	)		15,615			24,674			196,799			(237,088	)
Total liabilities and (deficit) equity	$	(237,088	)	$	258,768		$	15,615		$	33,358		$	188,732		$	259,385
Condensed Consolidating Statement of Comprehensive Income (Loss)
Three Months Ended September 30, 2014
(in thousands)	Lantheus			LMI			Guarantor			Non-Guarantor			Eliminations			Total
	Intermediate						Subsidiary			Subsidiaries
Revenues	$	—		$	66,927		$	—		$	13,637		$	(4,882	)	$	75,682
Cost of goods sold		—			36,243			—			12,683			(4,882	)		44,044
Gross profit		—			30,684			—			954			—			31,638
Operating expenses
Sales and marketing expenses		—			7,462			—			865			—			8,327
General and administrative expenses		—			8,222			20			480			—			8,722
Research and development expenses		—			2,953			—			96			—			3,049
Operating income (loss)		—			12,047			(20	)		(487	)		—			11,540
Interest expense, net		—			(10,649	)		—			64			—			(10,585	)
Other income, net		—			305			—			136			—			441
Equity in earnings (losses) of affiliates		1,452			(497	)		—			—			(955	)		—
Income (loss) before income taxes		1,452			1,206			(20	)		(287	)		(955	)		1,396
(Benefit) provision for income taxes		—			(246	)		—			190			—			(56	)
Net income (loss)		1,452			1,452			(20	)		(477	)		(955	)		1,452
Foreign currency translation		—			—			—			(671	)		—			(671	)
Equity in other comprehensive (loss) income of subsidiaries		(671	)		(671	)		—			—			1,342			—
Total comprehensive income (loss)	$	781		$	781		$	(20	)	$	(1,148	)	$	387		$	781
Condensed Consolidating Statement of Comprehensive Income (Loss)
Three Months Ended September 30, 2013
(in thousands)	Lantheus			LMI			Guarantor			Non-Guarantor			Eliminations			Total
	Intermediate						Subsidiary			Subsidiaries
Revenues	$	—		$	59,416		$	—		$	15,372		$	(4,403	)	$	70,385
Cost of goods sold		—			35,859			—			15,208			(4,403	)		46,664
Gross profit		—			23,557			—			164			—			23,721
Operating expenses
Sales and marketing expenses		—			7,641			—			835			—			8,476
General and administrative expenses		—			6,585			20			527			—			7,132
Research and development expenses		—			5,779			—			114			—			5,893
Impairment of land		—			—			6,788			—			—			6,788
Operating income (loss)		—			3,552			(6,808	)		(1,312	)		—			(4,568	)
Interest expense, net		—			(11,083	)		—			48			—			(11,035	)
Other income (expense), net		—			409			—			(149	)		—			260
Equity in earnings (losses) of affiliates		(15,064	)		(8,197	)		—			—			23,261			—
Income (loss) before income taxes		(15,064	)		(15,319	)		(6,808	)		(1,413	)		23,261			(15,343	)
(Benefit) provision for income taxes		—			(255	)		—			(24	)		—			(279	)
Net income (loss)		(15,064	)		(15,064	)		(6,808	)		(1,389	)		23,261			(15,064	)
Foreign currency translation		—			—			—			417			—			417
Equity in other comprehensive income (loss) of subsidiaries		417			417			—			—			(834	)		—
Total comprehensive income (loss)	$	(14,647	)	$	(14,647	)	$	(6,808	)	$	(972	)	$	22,427		$	(14,647	)
Condensed Consolidating Statement of Comprehensive Income (Loss)
Nine Months Ended September 30, 2014
(in thousands)	Lantheus			LMI			Guarantor			Non-Guarantor			Eliminations			Total
	Intermediate						Subsidiary			Subsidiaries
Revenues	$	—		$	196,435		$	—		$	42,067		$	(13,871	)	$	224,631
Cost of goods sold		—			108,111			—			37,633			(13,871	)		131,873
Gross profit		—			88,324			—			4,434			—			92,758
Operating expenses
Sales and marketing expenses		—			24,466			—			2,761			—			27,227
General and administrative expenses		—			24,822			60			1,682			—			26,564
Research and development expenses		—			8,656			—			302			—			8,958
Operating income (loss)		—			30,380			(60	)		(311	)		—			30,009
Interest expense, net		—			(31,896	)		—			192			—			(31,704	)
Other income (expense), net		—			80			—			(228	)		—			(148	)
Equity in earnings (losses) of affiliates		(1,469	)		(657	)		—			—			2,126			—
Income (loss) before income taxes		(1,469	)		(2,093	)		(60	)		(347	)		2,126			(1,843	)
(Benefit) provision for income taxes		—			(624	)		—			250			—			(374	)
Net income (loss)		(1,469	)		(1,469	)		(60	)		(597	)		2,126			(1,469	)
Foreign currency translation		—			—			—			(339	)		—			(339	)
Equity in other comprehensive income (loss) of subsidiaries		(339	)		(339	)		—			—			678			—
Total comprehensive income (loss)	$	(1,808	)	$	(1,808	)	$	(60	)	$	(936	)	$	2,804		$	(1,808	)
Condensed Consolidating Statement of Comprehensive Income (Loss)
Nine Months Ended September 30, 2013
(in thousands)	Lantheus			LMI			Guarantor			Non-Guarantor			Eliminations			Total
	Intermediate						Subsidiary			Subsidiaries
Revenues	$	—		$	180,453		$	—		$	47,228		$	(15,677	)	$	212,004
Cost of goods sold		—			115,962			—			44,239			(15,677	)		144,524
Gross profit		—			64,491			—			2,989			—			67,480
Operating expenses
Sales and marketing expenses		—			24,564			—			2,702			—			27,266
General and administrative expenses		—			23,844			60			1,774			—			25,678
Research and development expenses		—			25,200			—			228			—			25,428
Impairment of land		—			—			6,788			—			—			6,788
Operating loss		—			(9,117	)		(6,848	)		(1,715	)		—			(17,680	)
Interest expense, net		—			(32,458	)		—			135			—			(32,323	)
Other income (expense), net		—			1,039			—			(145	)		—			894
Equity in earnings (losses) of affiliates		(49,376	)		(8,552	)		—			—			57,928			—
Income (loss) before income taxes		(49,376	)		(49,088	)		(6,848	)		(1,725	)		57,928			(49,109	)
(Benefit) provision for income taxes		—			288			—			(21	)		—			267
Net income (loss)		(49,376	)		(49,376	)		(6,848	)		(1,704	)		57,928			(49,376	)
Foreign currency translation		—			—			—			(1,176	)		—			(1,176	)
Equity in other comprehensive income (loss) of subsidiaries		(1,176	)		(1,176	)		—			—			2,352			—
Total comprehensive income (loss)	$	(50,552	)	$	(50,552	)	$	(6,848	)	$	(2,880	)	$	60,280		$	(50,552	)
Condensed Consolidating Cash Flow Information
Nine Months September September 30, 2014
	Lantheus			LMI			Guarantor			Non-Guarantor			Eliminations			Total
	Intermediate						Subsidiary			Subsidiaries
Cash provided by operating activities	$	—		$	14,614		$	—		$	834		$	—		$	15,448
Cash flows from investing activities
Capital expenditures		—			(5,011	)		—			(292	)		—			(5,303	)
Payments from subsidiary		1,741			—			—			—			(1,741	)		—
Proceeds from sale of property, plant and equipment		—			227			—			—			—			227
Redemption of certificate of deposit-restricted		—			228			—			—			—			228
Cash provided by (used in) investing activities		1,741			(4,556	)		—			(292	)		(1,741	)		(4,848	)
Cash flows from financing activities
Proceeds from line of credit		—			5,500			—			—			—			5,500
Payments on line of credit		—			(5,500	)		—			—			—			(5,500	)
Payments on note payable		—			(52	)		—			—			—			(52	)
Deferred financing costs		—			(139	)		—			—			—			(139	)
Payments to parent		(1,741	)		(1,741	)		—			—			1,741			(1,741	)
Cash provided by (used in) financing activities		(1,741	)		(1,932	)		—			—			1,741			(1,932	)
Effect of foreign exchange rate on cash		—			—			—			(132	)		—			(132	)
Increase (decrease) in cash and cash equivalents		—			8,126			—			410			—			8,536
Cash and cash equivalents, beginning of period		—			11,995			—			4,674			—			16,669
Cash and cash equivalents, end of period	$	—		$	20,121		$	—		$	5,084		$	—		$	25,205
Condensed Consolidating Cash Flow Information
Nine Months Ended September 30, 2013
	Lantheus			LMI			Guarantor			Non-Guarantor			Eliminations			Total
	Intermediate						Subsidiary			Subsidiaries
Cash provided by (used in) operating activities	$	—		$	(13,054	)	$	—		$	2,970		$	(1,738	)	$	(11,822	)
Cash flows from investing activities
Capital expenditures		—			(3,621	)		—			(90	)		—			(3,711	)
Intercompany note		—			—			—			(2,249	)		2,249			—
Proceeds from dividend		—			4,174			—			—			(4,174	)		—
Cash provided by (used in) investing activities		—			553			—			(2,339	)		(1,925	)		(3,711	)
Cash flows from financing activities
Proceeds from line of credit		—			8,000			—			—			—			8,000
Payments on note payable		—			(1,174	)		—			—			—			(1,174	)
Deferred financing costs		—			(1,188	)		—			—			—			(1,188	)
Payments from parent		—			111			—			—			—			111
Intercompany note		—			2,249			—			—			(2,249	)		—
Payment of dividend		—			—			—			(5,912	)		5,912			—
Cash provided by (used in) financing activities		—			7,998			—			(5,912	)		3,663			5,749
Effect of foreign exchange rate on cash		—			—			—			(949	)		—			(949	)
Increase (decrease) in cash and cash equivalents		—			(4,503	)		—			(6,230	)		—			(10,733	)
Cash and cash equivalents, beginning of period		—			17,635			—			13,960			—			31,595
Cash and cash equivalents, end of period	$	—		$	13,132		$	—		$	7,730		$	—		$	20,862

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Revenue Recognition	'
	Revenue Recognition
	The Company recognizes revenue when evidence of an arrangement exists, title has passed, the risks and rewards of ownership have transferred to the customer, the selling price is fixed or determinable, and collectability is reasonably assured. For transactions for which revenue recognition criteria have not yet been met, the respective amounts are recorded as deferred revenue until such point in time the criteria are met and revenue can be recognized. Revenue is recognized net of reserves, which consist of allowances for returns and rebates.
	Revenue arrangements with multiple elements are divided into separate units of accounting if certain criteria are met, including whether the delivered element has stand-alone value to the customer. The arrangement’s consideration is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective evidence of fair value; (ii) third-party evidence of selling price; and (iii) best estimate of selling price. The best estimate of selling price reflects the Company’s best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis. The consideration allocated to each unit of accounting is then recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. Supply or service transactions may involve the charge of a nonrefundable initial fee with subsequent periodic payments for future products or services. The up-front fees, even if nonrefundable, are recognized as revenue as the products and/or services are delivered and performed over the term of the arrangement.
Inventory	'
	Inventory
	Inventory costs associated with product that has not yet received regulatory approval are capitalized if the Company believes there is probable future commercial use of the product and future economic benefits of the asset. If future commercial use of the product is not probable, then inventory costs associated with such product are expensed during the period the costs are incurred. For the nine months ended September 30, 2014, the Company expensed $1.7 million of such product costs in cost of goods sold relating to Neurolite that was manufactured by JHS. At September 30, 2014 and December 31, 2013, the Company had no capitalized inventories associated with product that did not have regulatory approval.
Goodwill	'
	Goodwill
	Goodwill is not amortized, but is instead tested for impairment at least annually and whenever events or circumstances indicate that it is more likely than not that it may be impaired. The Company has elected to perform the annual test for goodwill impairment as of October 31 of each year. All goodwill has been allocated to the U.S. operating segment.
	During the first quarter of 2013, the strategic shift in how the Company funds its R&D programs significantly altered the expected future costs and revenues associated with the Company’s agents in development. Accordingly, this action was deemed to be a triggering event for an evaluation of the recoverability of the Company’s goodwill as of March 31, 2013. The Company performed an interim impairment test and determined that there was no goodwill impairment as of March 31, 2013. There were no events as of September 30, 2014 and December 31, 2013 that triggered an interim impairment test of goodwill.
	The Company calculates the fair value of its reporting units using the income approach, which utilizes discounted forecasted future cash flows and the market approach which utilizes fair value multiples of comparable publicly traded companies. The discounted cash flows are based on the Company’s most recent long-term financial projections and are discounted using a risk adjusted rate of return, which is determined using estimates of market participant risk-adjusted weighted average costs of capital and reflects the risks associated with achieving future cash flows. The market approach is calculated using the guideline company method, where the Company uses market multiples derived from stock prices of companies engaged in the same or similar lines of business. A combination of the two methods is utilized to derive the fair value of the business in order to decrease the inherent risk associated with each model if used independently.

Fair_Value_of_Financial_Instru1

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Schedule of the Information about the Company's Assets and Liabilities Measured at Fair Value on a Recurring Basis	'
	Fair values determined by Level 3 inputs utilize unobservable data points for the asset or liability.
	September 30, 2014	Total fair		Quoted prices		Significant other		Significant
		value		in active		observable		unobservable
	(in thousands)			markets		inputs		inputs
				(Level 1)		(Level 2)		(Level 3)
	Money market	$	2,192	$	2,192	$	—	$	—
	Certificate of deposit—restricted		93		—		93		—
	Total	$	2,285	$	2,192	$	93	$	—
	December 31, 2013	Total fair		Quoted prices		Significant other		Significant
		value		in active		observable		unobservable
	(in thousands)			markets		inputs		inputs
				(Level 1)		(Level 2)		(Level 3)
	Money market	$	1,236	$	1,236	$	—	$	—
	Certificates of deposit—restricted		322		—		322		—
	Total	$	1,558	$	1,236	$	322	$	—

Inventory_Tables

Inventory (Tables)	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
Schedule of Inventory, Classified in Inventory or Other Long-term Assets	'
	Inventory, classified in inventory or other long-term assets, consisted of the following:
	(in thousands)	September 30,		December 31,
		2014		2013
	Raw materials	$	5,713	$	7,063
	Work in process		4,410		5,849
	Finished goods		6,302		5,398
	Inventory		16,425		18,310
	Other long-term assets		1,406		1,687
	Total	$	17,831	$	19,997

Property_Plant_and_Equipment_n1

Property, Plant and Equipment, net (Tables)	9 Months Ended
	Sep. 30, 2014
Property, Plant and Equipment [Abstract]	'
Schedule of Property, Plant and Equipment, Net	'
	Property, plant and equipment consisted of the following:
	(in thousands)	September 30,			December 31,
		2014			2013
	Land	$	14,950		$	14,950
	Buildings		67,470			65,787
	Machinery, equipment and fixtures		65,556			65,026
	Construction in progress		7,438			8,029
	Accumulated depreciation		(59,342	)		(56,139	)
	Property, plant and equipment, net	$	96,072		$	97,653

Asset_Retirement_Obligations_T

Asset Retirement Obligations (Tables)	9 Months Ended
	Sep. 30, 2014
Asset Retirement Obligation Disclosure [Abstract]	'
Schedule of Reconciliation of Company's Asset Retirement Obligations	'
	The following is a reconciliation of the Company’s asset retirement obligations for the nine months ended September 30, 2014:
	(in thousands)
	Balance at January 1, 2014	$	6,385
	Capitalization		277
	Accretion expense		582
	Balance at September 30, 2014	$	7,244

Intangibles_net_Tables

Intangibles, net (Tables)	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Intangibles, Net	'
	Intangibles, net consisted of the following:
		September 30, 2014
	(in thousands)	Cost		Accumulated		Net		Amortization
				amortization				Method
	Trademarks	$	13,540	$	4,662	$	8,878	Straight-line
	Customer relationships		105,942		88,094		17,848	Accelerated
	Other patents		42,780		40,303		2,477	Straight-line
		$	162,262	$	133,059	$	29,203
		December 31, 2013
	(in thousands)	Cost		Accumulated		Net		Amortization
				amortization				Method
	Trademarks	$	13,540	$	3,298	$	10,242	Straight-line
	Customer relationships		106,298		84,476		21,822	Accelerated
	Other patents		42,780		39,846		2,934	Straight-line
		$	162,618	$	127,620	$	34,998
Schedule of Expected Future Amortization Expense Related to Intangible Assets	'
	Expected future amortization expense related to the intangible assets is as follows:
	(in thousands)
	Remainder of 2014	$	1,902
	2015		6,021
	2016		5,337
	2017		3,521
	2018		2,792
	2019 and thereafter		9,630
		$	29,203

Accrued_Expenses_and_Other_Lia1

Accrued Expenses and Other Liabilities (Tables)	9 Months Ended
	Sep. 30, 2014
Text Block [Abstract]	'
Schedule of Accrued Expenses and Other Liabilities	'
	Accrued expenses and other liabilities are comprised of the following:
	(in thousands)	September 30,		December 31,
		2014		2013
	Compensation and benefits	$	10,875	$	10,209
	Accrued interest		14,719		4,989
	Accrued professional fees		1,713		1,361
	Research and development services		220		338
	Freight, distribution and operations		3,187		3,432
	Accrued loss on firm purchase commitment		—		1,315
	Marketing expense		1,243		749
	Accrued rebates, discounts and chargebacks		2,729		1,739
	Other		402		1,360
		$	35,088	$	25,492

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Assumptions used for Estimating Fair Value of Each Option Award on Date of Grant using Black-Scholes Valuation Model	'
	The Company uses the following Black-Scholes inputs to determine the fair value of new stock option grants.
		Three Months						Nine Months
		Ended September 30,						Ended September 30,
		2014			2013			2014		2013
	Expected volatility		—			36	%	33 - 35%		36%
	Expected dividends		—			—		—		—
	Expected life (in years)		—			6.3		5.5 - 6.3		5.5 - 6.3
	Risk-free interest rate		—			1.7	%	1.5 – 1.9%		0.7 - 1.7%
Schedule of Option Activity	'
	A summary of option activity for 2014 is presented below:
		Time Based			Performance			Total			Weighted		Weighted		Aggregate
					Based						Average		Average		Intrinsic
											Exercise		Remaining		Value
											Price		Contractual
													Term
	Outstanding at January 1, 2014		2,761,037			1,097,425			3,858,462		$	4.89		6.9	$	6,777,000
	Options granted		74,664			—			74,664			5.98
	Options cancelled		(21,500	)		(6,952	)		(28,452	)		4.88
	Options exercised		(4,500	)		(1,737	)		(6,237	)		2
	Options forfeited or expired		(31,000	)		(7,880	)		(38,880	)		7.29
	Outstanding at September 30, 2014		2,778,701			1,080,856			3,859,557			4.89		6.2	$	3,979,000
	Vested and expected to vest at September 30, 2014		2,715,687			701,755			3,417,442			4.64		5.9	$	3,979,000
	Exercisable at September 30, 2014		1,815,393			548,302			2,363,695			3.58		4.7	$	3,979,000
Schedule of Stock-Based Compensation Expense Recognized	'
	Stock-based compensation expense for both time based and performance based awards was recognized in the condensed consolidated statements of comprehensive income (loss) as follows:
		Three Months						Nine Months
		Ended						Ended
		September 30,						September 30,
	(in thousands)	2014			2013			2014			2013
	Cost of goods sold	$	32		$	26		$	104		$	56
	Sales and marketing		34			46			116			86
	General and administrative		151			62			474			553
	Research and development		30			38			88			40
	Total stock-based compensation expense	$	247		$	172		$	782		$	735

Other_Expense_Income_net_Table

Other (Expense) Income, net (Tables)	9 Months Ended
	Sep. 30, 2014
Other Income and Expenses [Abstract]	'
Schedule of Other (Expense) Income, Net	'
	Other (expense) income, net consisted of the following:
		Three Months					Nine Months
		Ended					Ended
		September 30,					September 30,
	(in thousands)	2014		2013			2014			2013
	Foreign currency (losses) gains	$	82	$	(174	)	$	(311	)	$	(180	)
	Tax indemnification income		359		434			163			706
	Other income		—		—			—			368
	Total other income (expense), net	$	441	$	260		$	(148	)	$	894

Segment_Information_Tables

Segment Information (Tables)	9 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
Schedule of Selected Information for Each Business Segment	'
	Selected information for each business segment is as follows (in thousands):
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2014			2013			2014			2013
	Revenues
	U.S.	$	64,311		$	56,407		$	188,679		$	174,167
	International		16,253			18,381			49,823			53,514
	Total revenue, including inter-segment		80,564			74,788			238,502			227,681
	Less inter-segment revenue		(4,882	)		(4,403	)		(13,871	)		(15,677	)
		$	75,682		$	70,385		$	224,631		$	212,004
	Revenues from external customers
	U.S.	$	59,429		$	52,004		$	174,808		$	158,490
	International		16,253			18,381			49,823			53,514
		$	75,682		$	70,385		$	224,631		$	212,004
	Operating income (loss)
	U.S.	$	10,493		$	(5,116	)	$	25,930		$	(18,414	)
	International		1,009			(54	)		3,653			913
	Total operating income (loss), including inter-segment		11,502			(5,170	)		29,583			(17,501	)
	Inter-segment operating income (loss)		38			602			426			(179	)
	Operating income (loss)		11,540			(4,568	)		30,009			(17,680	)
	Interest expense, net		(10,585	)		(11,035	)		(31,704	)		(32,323	)
	Other income (expense), net		441			260			(148	)		894
	Income (loss) before income taxes	$	1,396		$	(15,343	)	$	(1,843	)	$	(49,109	)
		September 30,			December 31,
		2014			2013
	Total Assets
	U.S.	$	232,491		$	232,973
	International		25,563			26,412
		$	258,054		$	259,385

Guarantor_Financial_Informatio1

Guarantor Financial Information (Tables)	9 Months Ended
	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Schedule of Condensed Consolidating Balance Sheet Information	'
	Condensed Consolidating Balance Sheet Information
	September 30, 2014
	(in thousands)	Lantheus			LMI			Guarantor			Non-			Eliminations			Total
		Intermediate						Subsidiary			Guarantor
											Subsidiaries
	Assets:
	Current assets
	Cash and cash equivalents	$	—		$	20,121		$	—		$	5,084		$	—		$	25,205
	Accounts receivable, net		—			30,611			—			10,549			—			41,160
	Intercompany accounts receivable		—			2,962			—			—			(2,962	)		—
	Inventory		—			13,500			—			2,925			—			16,425
	Income tax receivable		—			423			—			25			—			448
	Deferred tax assets		—			—			—			12			—			12
	Other current assets		—			3,916			—			265			—			4,181
	Total current assets		—			71,533			—			18,860			(2,962	)		87,431
	Property, plant and equipment, net		—			75,510			15,555			5,007			—			96,072
	Capitalized software development costs, net		—			1,828			—			1			—			1,829
	Intangibles, net		—			26,628			—			2,575			—			29,203
	Goodwill		—			15,714			—			—			—			15,714
	Deferred financing costs		—			7,969			—			—			—			7,969
	Deferred tax assets		—			—			—			45			—			45
	Investment in subsidiaries		(240,416	)		39,293			—			—			201,123			—
	Intercompany note receivable		—			—			—			5,568			(5,568	)		—
	Other long-term assets		—			19,591			—			200			—			19,791
	Total assets	$	(240,416	)	$	258,066		$	15,555		$	32,256		$	192,593		$	258,054
	Liabilities and (deficit) equity:
	Current liabilities
	Line of credit	$	—		$	8,000		$	—		$	—		$	—		$	8,000
	Accounts payable		—			13,810			—			1,573			—			15,383
	Intercompany accounts payable		—			—			—			2,962			(2,962	)		—
	Accrued expenses and other liabilities		—			31,944			—			3,144			—			35,088
	Deferred tax liability		—			—			—			57			—			57
	Deferred revenue		—			1,063			—			—			—			1,063
	Total current liabilities		—			54,817			—			7,736			(2,962	)		59,591
	Asset retirement obligations		—			7,049			—			195			—			7,244
	Long-term debt, net		—			399,220			—			—			—			399,220
	Intercompany note payable		—			5,568			—			—			(5,568	)		—
	Deferred tax liability		—			—			—			8			—			8
	Other long-term liabilities		—			31,828			—			579			—			32,407
	Total liabilities		—			498,482			—			8,518			(8,530	)		498,470
	(Deficit) equity		(240,416	)		(240,416	)		15,555			23,738			201,123			(240,416	)
	Total liabilities and (deficit) equity	$	(240,416	)	$	258,066		$	15,555		$	32,256		$	192,593		$	258,054
	Condensed Consolidating Balance Sheet Information
	December 31, 2013
	(in thousands)	Lantheus			LMI			Guarantor			Non-			Eliminations			Total
		Intermediate						Subsidiary			Guarantor
											Subsidiaries
	Assets:
	Current assets
	Cash and cash equivalents	$	—		$	11,995		$	—		$	4,674		$	—		$	16,669
	Accounts receivable, net		—			28,099			—			10,811			—			38,910
	Intercompany accounts receivable		—			2,671			—			—			(2,671	)		—
	Inventory		—			15,414			—			2,896			—			18,310
	Income tax receivable		—			297			—			28			—			325
	Deferred tax assets		—			—			—			18			—			18
	Other current assets		—			2,906			—			181			—			3,087
	Total current assets		—			61,382			—			18,608			(2,671	)		77,319
	Property, plant and equipment, net		—			76,068			15,615			5,970			—			97,653
	Capitalized software development costs, net		—			1,468			—			2			—			1,470
	Intangibles, net		—			31,838			—			3,160			—			34,998
	Goodwill		—			15,714			—			—			—			15,714
	Deferred financing costs		—			9,639			—			—			—			9,639
	Deferred tax assets		—			—			—			15			—			15
Investment in subsidiaries		(237,088	)		40,289			—			—			196,799			—
Intercompany note receivable		—			—			—			5,396			(5,396	)		—
Other long-term assets		—			22,370			—			207			—			22,577
Total assets	$	(237,088	)	$	258,768		$	15,615		$	33,358		$	188,732		$	259,385
Liabilities and (deficit) equity:
Current liabilities
Line of credit	$	—		$	8,000		$	—		$	—		$	—		$	8,000
Accounts payable		—			16,672			—			1,431			—			18,103
Intercompany accounts payable		—			—			—			2,671			(2,671	)		—
Accrued expenses and other liabilities		—			21,409			—			4,083			—			25,492
Deferred tax liability		—			—			—			57			—			57
Deferred revenue		—			3,979			—			—			—			3,979
Total current liabilities		—			50,060			—			8,242			(2,671	)		55,631
Asset retirement obligations		—			6,212			—			173			—			6,385
Long-term debt, net		—			399,037			—			—			—			399,037
Intercompany note payable		—			5,396			—			—			(5,396	)		—
Deferred tax liability		—			—			—			12			—			12
Other long-term liabilities		—			35,151			—			257			—			35,408
Total liabilities		—			495,856			—			8,684			(8,067	)		496,473
(Deficit) equity		(237,088	)		(237,088	)		15,615			24,674			196,799			(237,088	)
Total liabilities and (deficit) equity	$	(237,088	)	$	258,768		$	15,615		$	33,358		$	188,732		$	259,385
Schedule of Condensed Consolidating Statement of Comprehensive Income (Loss)	'
	Condensed Consolidating Statement of Comprehensive Income (Loss)
	Three Months Ended September 30, 2014
	(in thousands)	Lantheus			LMI			Guarantor			Non-Guarantor			Eliminations			Total
		Intermediate						Subsidiary			Subsidiaries
	Revenues	$	—		$	66,927		$	—		$	13,637		$	(4,882	)	$	75,682
	Cost of goods sold		—			36,243			—			12,683			(4,882	)		44,044
	Gross profit		—			30,684			—			954			—			31,638
	Operating expenses
	Sales and marketing expenses		—			7,462			—			865			—			8,327
	General and administrative expenses		—			8,222			20			480			—			8,722
	Research and development expenses		—			2,953			—			96			—			3,049
	Operating income (loss)		—			12,047			(20	)		(487	)		—			11,540
	Interest expense, net		—			(10,649	)		—			64			—			(10,585	)
	Other income, net		—			305			—			136			—			441
	Equity in earnings (losses) of affiliates		1,452			(497	)		—			—			(955	)		—
	Income (loss) before income taxes		1,452			1,206			(20	)		(287	)		(955	)		1,396
	(Benefit) provision for income taxes		—			(246	)		—			190			—			(56	)
	Net income (loss)		1,452			1,452			(20	)		(477	)		(955	)		1,452
	Foreign currency translation		—			—			—			(671	)		—			(671	)
	Equity in other comprehensive (loss) income of subsidiaries		(671	)		(671	)		—			—			1,342			—
	Total comprehensive income (loss)	$	781		$	781		$	(20	)	$	(1,148	)	$	387		$	781
	Condensed Consolidating Statement of Comprehensive Income (Loss)
	Three Months Ended September 30, 2013
	(in thousands)	Lantheus			LMI			Guarantor			Non-Guarantor			Eliminations			Total
		Intermediate						Subsidiary			Subsidiaries
	Revenues	$	—		$	59,416		$	—		$	15,372		$	(4,403	)	$	70,385
	Cost of goods sold		—			35,859			—			15,208			(4,403	)		46,664
	Gross profit		—			23,557			—			164			—			23,721
	Operating expenses
	Sales and marketing expenses		—			7,641			—			835			—			8,476
	General and administrative expenses		—			6,585			20			527			—			7,132
	Research and development expenses		—			5,779			—			114			—			5,893
	Impairment of land		—			—			6,788			—			—			6,788
	Operating income (loss)		—			3,552			(6,808	)		(1,312	)		—			(4,568	)
	Interest expense, net		—			(11,083	)		—			48			—			(11,035	)
	Other income (expense), net		—			409			—			(149	)		—			260
	Equity in earnings (losses) of affiliates		(15,064	)		(8,197	)		—			—			23,261			—
	Income (loss) before income taxes		(15,064	)		(15,319	)		(6,808	)		(1,413	)		23,261			(15,343	)
	(Benefit) provision for income taxes		—			(255	)		—			(24	)		—			(279	)
	Net income (loss)		(15,064	)		(15,064	)		(6,808	)		(1,389	)		23,261			(15,064	)
	Foreign currency translation		—			—			—			417			—			417
	Equity in other comprehensive income (loss) of subsidiaries		417			417			—			—			(834	)		—
	Total comprehensive income (loss)	$	(14,647	)	$	(14,647	)	$	(6,808	)	$	(972	)	$	22,427		$	(14,647	)
	Condensed Consolidating Statement of Comprehensive Income (Loss)
	Nine Months Ended September 30, 2014
	(in thousands)	Lantheus			LMI			Guarantor			Non-Guarantor			Eliminations			Total
		Intermediate						Subsidiary			Subsidiaries
	Revenues	$	—		$	196,435		$	—		$	42,067		$	(13,871	)	$	224,631
	Cost of goods sold		—			108,111			—			37,633			(13,871	)		131,873
	Gross profit		—			88,324			—			4,434			—			92,758
	Operating expenses
	Sales and marketing expenses		—			24,466			—			2,761			—			27,227
	General and administrative expenses		—			24,822			60			1,682			—			26,564
	Research and development expenses		—			8,656			—			302			—			8,958
	Operating income (loss)		—			30,380			(60	)		(311	)		—			30,009
	Interest expense, net		—			(31,896	)		—			192			—			(31,704	)
	Other income (expense), net		—			80			—			(228	)		—			(148	)
	Equity in earnings (losses) of affiliates		(1,469	)		(657	)		—			—			2,126			—
	Income (loss) before income taxes		(1,469	)		(2,093	)		(60	)		(347	)		2,126			(1,843	)
	(Benefit) provision for income taxes		—			(624	)		—			250			—			(374	)
	Net income (loss)		(1,469	)		(1,469	)		(60	)		(597	)		2,126			(1,469	)
	Foreign currency translation		—			—			—			(339	)		—			(339	)
	Equity in other comprehensive income (loss) of subsidiaries		(339	)		(339	)		—			—			678			—
Total comprehensive income (loss)	$	(1,808	)	$	(1,808	)	$	(60	)	$	(936	)	$	2,804		$	(1,808	)
Condensed Consolidating Statement of Comprehensive Income (Loss)
Nine Months Ended September 30, 2013
(in thousands)	Lantheus			LMI			Guarantor			Non-Guarantor			Eliminations			Total
	Intermediate						Subsidiary			Subsidiaries
Revenues	$	—		$	180,453		$	—		$	47,228		$	(15,677	)	$	212,004
Cost of goods sold		—			115,962			—			44,239			(15,677	)		144,524
Gross profit		—			64,491			—			2,989			—			67,480
Operating expenses
Sales and marketing expenses		—			24,564			—			2,702			—			27,266
General and administrative expenses		—			23,844			60			1,774			—			25,678
Research and development expenses		—			25,200			—			228			—			25,428
Impairment of land		—			—			6,788			—			—			6,788
Operating loss		—			(9,117	)		(6,848	)		(1,715	)		—			(17,680	)
Interest expense, net		—			(32,458	)		—			135			—			(32,323	)
Other income (expense), net		—			1,039			—			(145	)		—			894
Equity in earnings (losses) of affiliates		(49,376	)		(8,552	)		—			—			57,928			—
Income (loss) before income taxes		(49,376	)		(49,088	)		(6,848	)		(1,725	)		57,928			(49,109	)
(Benefit) provision for income taxes		—			288			—			(21	)		—			267
Net income (loss)		(49,376	)		(49,376	)		(6,848	)		(1,704	)		57,928			(49,376	)
Foreign currency translation		—			—			—			(1,176	)		—			(1,176	)
Equity in other comprehensive income (loss) of subsidiaries		(1,176	)		(1,176	)		—			—			2,352			—
Total comprehensive income (loss)	$	(50,552	)	$	(50,552	)	$	(6,848	)	$	(2,880	)	$	60,280		$	(50,552	)
Schedule of Condensed Consolidating Cash Flow Information	'
	Condensed Consolidating Cash Flow Information
	Nine Months September September 30, 2014
		Lantheus			LMI			Guarantor			Non-Guarantor			Eliminations			Total
		Intermediate						Subsidiary			Subsidiaries
	Cash provided by operating activities	$	—		$	14,614		$	—		$	834		$	—		$	15,448
	Cash flows from investing activities
	Capital expenditures		—			(5,011	)		—			(292	)		—			(5,303	)
	Payments from subsidiary		1,741			—			—			—			(1,741	)		—
	Proceeds from sale of property, plant and equipment		—			227			—			—			—			227
	Redemption of certificate of deposit-restricted		—			228			—			—			—			228
	Cash provided by (used in) investing activities		1,741			(4,556	)		—			(292	)		(1,741	)		(4,848	)
	Cash flows from financing activities
	Proceeds from line of credit		—			5,500			—			—			—			5,500
	Payments on line of credit		—			(5,500	)		—			—			—			(5,500	)
	Payments on note payable		—			(52	)		—			—			—			(52	)
	Deferred financing costs		—			(139	)		—			—			—			(139	)
	Payments to parent		(1,741	)		(1,741	)		—			—			1,741			(1,741	)
	Cash provided by (used in) financing activities		(1,741	)		(1,932	)		—			—			1,741			(1,932	)
	Effect of foreign exchange rate on cash		—			—			—			(132	)		—			(132	)
	Increase (decrease) in cash and cash equivalents		—			8,126			—			410			—			8,536
	Cash and cash equivalents, beginning of period		—			11,995			—			4,674			—			16,669
	Cash and cash equivalents, end of period	$	—		$	20,121		$	—		$	5,084		$	—		$	25,205
	Condensed Consolidating Cash Flow Information
	Nine Months Ended September 30, 2013
		Lantheus			LMI			Guarantor			Non-Guarantor			Eliminations			Total
		Intermediate						Subsidiary			Subsidiaries
	Cash provided by (used in) operating activities	$	—		$	(13,054	)	$	—		$	2,970		$	(1,738	)	$	(11,822	)
	Cash flows from investing activities
	Capital expenditures		—			(3,621	)		—			(90	)		—			(3,711	)
	Intercompany note		—			—			—			(2,249	)		2,249			—
	Proceeds from dividend		—			4,174			—			—			(4,174	)		—
	Cash provided by (used in) investing activities		—			553			—			(2,339	)		(1,925	)		(3,711	)
	Cash flows from financing activities
	Proceeds from line of credit		—			8,000			—			—			—			8,000
	Payments on note payable		—			(1,174	)		—			—			—			(1,174	)
	Deferred financing costs		—			(1,188	)		—			—			—			(1,188	)
	Payments from parent		—			111			—			—			—			111
	Intercompany note		—			2,249			—			—			(2,249	)		—
	Payment of dividend		—			—			—			(5,912	)		5,912			—
	Cash provided by (used in) financing activities		—			7,998			—			(5,912	)		3,663			5,749
	Effect of foreign exchange rate on cash		—			—			—			(949	)		—			(949	)
	Increase (decrease) in cash and cash equivalents		—			(4,503	)		—			(6,230	)		—			(10,733	)
	Cash and cash equivalents, beginning of period		—			17,635			—			13,960			—			31,595
	Cash and cash equivalents, end of period	$	—		$	13,132		$	—		$	7,730		$	—		$	20,862

Business_Overview_Additional_I

Business Overview - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended			9 Months Ended	0 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014
	Item		Item			Revolving Line of Credit [Member]	Revolving Line of Credit [Member]	Minimum [Member]	Neurolite [Member]	Cardiolite [Member]	Definity and Cardiolite [Member]
								Item	Item	Item	Item
Business Overview	'	'	'	'	'	'	'	'	'	'	'
Number of commercial products	10	'	10	'	'	'	'	'	'	'	'
Number of radiopharmacies distributions	350	'	350	'	'	'	'	'	'	'	'
Number of radiopharmacies owned	9	'	9	'	'	'	'	'	'	'	'
Net loss	$1,452,000	($15,064,000)	($1,469,000)	($49,376,000)	($61,678,000)	'	'	'	'	'	'
Accumulated deficit	-239,807,000	'	-239,807,000	'	-238,338,000	'	'	'	'	'	'
Number of manufacturers	'	'	'	'	'	'	'	'	'	1	2
Number of supplier	'	'	'	'	'	'	'	'	0	'	'
Borrowing Base	'	'	'	'	'	47,500,000	'	'	'	'	'
Unfunded Standby Letter of Credit outstanding	'	'	'	'	'	8,800,000	8,800,000	'	'	'	'
Amount outstanding	'	'	'	'	'	8,100,000	'	'	'	'	'
Available Borrowing capacity	'	'	'	'	'	$30,600,000	'	'	'	'	'
Number of strategic partners to engage with for further development and commercialization of development candidates	'	'	'	'	'	'	'	1	'	'	'
Number of other development candidates for which strategic partners to assist with the on-going development activities	'	'	2	'	'	'	'	'	'	'	'

Summary_of_Significant_Account2

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	3 Months Ended			9 Months Ended		12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Mar. 31, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
				Event		Event
				Method
Schedule Of Accounting Policies [Line Items]	'	'	'	'	'	'
Cost of goods sold	$44,044,000	$46,664,000	'	$131,873,000	$144,524,000	'
Capitalized inventories	'	'	'	0	'	0
Goodwill impairment	'	'	0	'	'	'
Number of events that triggered an interim impairment test	'	'	'	0	'	0
Number of methods utilized to derive the fair value of the business	'	'	'	2	'	'
Neurolite [Member]	'	'	'	'	'	'
Schedule Of Accounting Policies [Line Items]	'	'	'	'	'	'
Cost of goods sold	'	'	'	$1,700,000	'	'

Fair_Value_of_Financial_Instru2

Fair Value of Financial Instruments - Schedule of the Information about the Company's Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) (Recurring Basis [Member], USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Total Fair Value [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash and cash equivalents, fair value	$2,192	$1,236
Restricted investments	93	322
Total	2,285	1,558
Quoted Prices in Active Markets (Level 1) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash and cash equivalents, fair value	2,192	1,236
Restricted investments	'	'
Total	2,192	1,236
Significant Other Observable Inputs (Level 2) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash and cash equivalents, fair value	'	'
Restricted investments	93	322
Total	93	322
Significant Unobservable Inputs (Level 3) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash and cash equivalents, fair value	'	'
Restricted investments	'	'
Total	'	'

Fair_Value_of_Financial_Instru3

Fair Value of Financial Instruments - Additional Information (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2013	Dec. 31, 2012
Fair Value Asset Measured On Recurring Basis [Line Items]	'	'	'	'
Cash and cash equivalents, carrying value	$25,205,000	$16,669,000	$20,862,000	$31,595,000
Face value of debt	400,000,000	400,000,000	'	'
Recurring Basis [Member] | Significant Other Observable Inputs (Level 2) [Member]	'	'	'	'
Fair Value Asset Measured On Recurring Basis [Line Items]	'	'	'	'
Estimated fair value of the debt	392,000,000	356,000,000	'	'
Money Market Funds [Member]	'	'	'	'
Fair Value Asset Measured On Recurring Basis [Line Items]	'	'	'	'
Cash and cash equivalents, carrying value	2,200,000	1,200,000	'	'
Cash-On-Hand [Member]	'	'	'	'
Fair Value Asset Measured On Recurring Basis [Line Items]	'	'	'	'
Cash and cash equivalents, carrying value	23,000,000	15,500,000	'	'
Certificates of Deposit [Member]	'	'	'	'
Fair Value Asset Measured On Recurring Basis [Line Items]	'	'	'	'
Restricted investments, current	200,000	200,000	'	'
Restricted investments, noncurrent	$100,000	$100,000	'	'

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Income Tax [Line Items]	'	'	'	'
Provision (benefit) for income taxes	($56,000)	($279,000)	($374,000)	$267,000
Tax benefit recognized with the reversal of uncertain tax positions upon expiration of statute of limitations for 2010 U.S. tax return	900,000	'	2,700,000	'
Tax benefit recognized with the reversal of uncertain tax positions upon expiration of statute of limitations for 2009 U.S. tax return	'	800,000	'	800,000
Amount of unrecognized tax benefits primarily relating to transfer pricing which may be recognized within the next twelve months due to the closing of the statute of limitation	400,000	'	400,000	'
BMS [Member]	'	'	'	'
Income Tax [Line Items]	'	'	'	'
Net effect on earnings related to deferred tax liabilities	'	'	0	'
Net effect on cash flow related to deferred tax liabilities	'	'	0	'
Settlement expense	'	'	$6,300,000	'

Inventory_Schedule_of_Inventor

Inventory - Schedule of Inventory, Classified in Inventory or Other Long-term Assets (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Raw materials	$5,713	$7,063
Work in process	4,410	5,849
Finished goods	6,302	5,398
Inventory	16,425	18,310
Other long-term assets	1,406	1,687
Total	$17,831	$19,997

Inventory_Additional_Informati

Inventory - Additional Information (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Non-current raw materials	$1.20	$1.70
Non-current finished goods	$0.20	'

Property_Plant_and_Equipment_n2

Property, Plant and Equipment, net - Schedule of Property, Plant and Equipment (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Property, Plant and Equipment [Abstract]	'	'
Accumulated depreciation	($59,342)	($56,139)
Property, plant and equipment, net	96,072	97,653
Land [Member]	'	'
Property, Plant and Equipment [Abstract]	'	'
Property, plant and equipment, gross	14,950	14,950
Buildings [Member]	'	'
Property, Plant and Equipment [Abstract]	'	'
Property, plant and equipment, gross	67,470	65,787
Machinery, Equipment and Fixtures [Member]	'	'
Property, Plant and Equipment [Abstract]	'	'
Property, plant and equipment, gross	65,556	65,026
Construction in Progress [Member]	'	'
Property, Plant and Equipment [Abstract]	'	'
Property, plant and equipment, gross	$7,438	$8,029

Property_Plant_and_Equipment_n3

Property, Plant and Equipment, net - Additional Information (Detail) (USD $)	3 Months Ended			9 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Depreciation expense	$2,200,000	'	$2,300,000	$6,500,000	$7,100,000
Property, plant and equipment, net	96,072,000	97,653,000	'	96,072,000	'
Impairment charge on assets held for sale	'	'	6,788,000	'	6,788,000
Net proceeds from sale of excess land	'	1,100,000	1,100,000	'	'
International [Member] | Significant Unobservable Inputs (Level 3) [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Impairment charge on assets held for sale	'	'	6,788,000	'	'
Spare Parts [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property, plant and equipment, gross	2,500,000	2,500,000	'	2,500,000	'
Fixed Assets Dedicated to R&D Activities [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property, plant and equipment, net	$5,200,000	'	'	$5,200,000	'

Asset_Retirement_Obligations_A

Asset Retirement Obligations - Additional Information (Detail) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014
Asset Retirement Obligation Disclosure [Abstract]	'
Financial assurance in form of surety bond	$28.20
Unfunded Standby Letter of Credit	8.8
Asset retirement obligation liabilities expected present value	$26.60

Asset_Retirement_Obligations_S

Asset Retirement Obligations - Schedule of Reconciliation of Company's Asset Retirement Obligations (Detail) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014
Reconciliation of the asset retirement obligations	'
Balance at the beginning of the period	$6,385
Capitalization	277
Accretion expense	582
Balance at the end of the period	$7,244

Intangibles_Net_Schedule_of_In

Intangibles, Net - Schedule of Intangibles, Net (Detail) (USD $)	9 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]	'	'
Cost	$162,262	$162,618
Accumulated amortization	133,059	127,620
Net	29,203	34,998
Trademarks [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Cost	13,540	13,540
Accumulated amortization	4,662	3,298
Net	8,878	10,242
Amortization Method	'Straight-line	'Straight-line
Customer Relationships [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Cost	105,942	106,298
Accumulated amortization	88,094	84,476
Net	17,848	21,822
Amortization Method	'Accelerated	'Accelerated
Other Patents [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Cost	42,780	42,780
Accumulated amortization	40,303	39,846
Net	$2,477	$2,934
Amortization Method	'Straight-line	'Straight-line

Intangibles_Net_Additional_Inf

Intangibles, Net - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Finite-Lived Intangible Assets [Line Items]	'	'	'	'
Impairment charges	'	'	'	$1,034,000
Amortization expense	1,900,000	3,600,000	5,700,000	10,800,000
Customer Relationships [Member]	'	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'	'
Impairment charges	'	$1,000,000	'	$1,000,000

Intangibles_Net_Schedule_of_Ex

Intangibles, Net - Schedule of Expected Future Amortization Expense Related to Intangible Assets (Detail) (USD $)	Sep. 30, 2014
In Thousands, unless otherwise specified
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]	'
Remainder of 2014	$1,902
2015	6,021
2016	5,337
2017	3,521
2018	2,792
2019 and thereafter	9,630
Total	$29,203

Accrued_Expenses_and_Other_Lia2

Accrued Expenses and Other Liabilities - Schedule of Accrued Expenses and Other Liabilities (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Payables and Accruals [Abstract]	'	'
Compensation and benefits	$10,875	$10,209
Accrued interest	14,719	4,989
Accrued professional fees	1,713	1,361
Research and development services	220	338
Freight, distribution and operations	3,187	3,432
Accrued loss on firm purchase commitment	'	1,315
Marketing expense	1,243	749
Accrued rebates, discounts and chargebacks	2,729	1,739
Other	402	1,360
Accrued expenses	$35,088	$25,492

Accrued_Expenses_and_Other_Lia3

Accrued Expenses and Other Liabilities - Additional Information (Detail) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Accrued Expenses and other liabilities	'
Contract loss associated with the portion of the committed purchases	$1,315
Ablavar [Member]	'
Accrued Expenses and other liabilities	'
Contract loss associated with the portion of the committed purchases	$1,300

Financing_Arrangements_Additio

Financing Arrangements - Additional Information (Detail) (USD $)	0 Months Ended	9 Months Ended
In Millions, unless otherwise specified	Jun. 24, 2014	Sep. 30, 2014	Dec. 31, 2013
Senior Notes [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Aggregate principal amount outstanding	'	$400	'
Notes interest rate (as a percent)	'	9.75%	'
Maturity of the notes	'	15-May-17	'
Notes payment term, description	'	'The Notes bear interest at a rate of 9.750% per year, payable on May 15 and November 15 of each year.	'
Revolving Line of Credit [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Maturity of the notes	'	3-Jul-18	'
Maximum borrowing capacity	42.5	'	'
Amended maximum borrowing capacity	50	'	'
Description of variable rate basis	'	'On June 24, 2014, the Company executed an amendment to the Facility which, (i) increased the committed availability for total borrowings under the Facility from $42.5 million to $50.0 million, (ii) set the interest at LIBOR plus 2.00% or the Reference Rate (as defined in the agreement) plus 1.00%, (iii) set the unused line fee at 0.375%, and (iv) further modified certain definitions.	'
Unused line of credit fee (as a percent)	0.38%	'	'
Fees and expenses incurred in connection with amendment	'	0.2	'
Period prior to maturity of senior notes on which credit facility expires	'	'91 days	'
Debt instrument maturity description	'	'The Facility expires on the earlier of (i) July 3, 2018 or (ii) if the outstanding Notes are not refinanced in full, the date that is 91 days before the maturity thereof, at which time all outstanding borrowings are due and payable.	'
Unfunded Standby Letter of Credit outstanding	'	8.8	8.8
Letter of credit, expiration date	'	5-Feb-15	'
Renewal period of unfunded standby letter of credit	'	'1 year	'
Period required to notify in writing the cancellation of automatic renewal of debt instrument	'	'60 days	'
Unfunded standby letter of credit payment term	'	'The unfunded Standby Letter of Credit requires an annual fee, payable quarterly, which is set at LIBOR plus a spread of 2.00%	'
Borrowing Base	'	47.5	'
Amount outstanding	'	8.1	'
Available Borrowing capacity	'	$30.60	'
Revolving Line of Credit [Member] | LIBOR [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Basis spread on variable rate (as a percent)	2.00%	2.00%	'
Revolving Line of Credit [Member] | Reference Rate [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Basis spread on variable rate (as a percent)	1.00%	'	'

StockBased_Compensation_Additi

Stock-Based Compensation - Additional Information (Detail) (USD $)

3 Months Ended

9 Months Ended

12 Months Ended

0 Months Ended

9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Aug. 04, 2013

Aug. 05, 2013

Aug. 04, 2013

Sep. 30, 2014

Sep. 30, 2014

Liability-Based Awards [Member]

Liability-Based Awards [Member]

Performance Based Stock Options [Member]

2008 Plan [Member]

2013 Plan [Member]

2013 Plan [Member]

Minimum [Member]

Maximum [Member]

Time Based Stock Options [Member]

Time Based Stock Options [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Number of further grants to be issued (in shares)

'

'

'

'

'

'

'

0

'

'

'

'

Maximum number of shares that may be issued pursuant to awards

'

'

'

'

'

'

'

'

2,700,000

1,500,000

'

'

Vesting period

'

'

'

'

'

'

'

'

'

'

'4 years

'5 years

Contractual term

'

'

'10 years

'

'

'

'

'

'

'

'

'

Weighted average grant-date fair value of options granted

'

$2.53

$2.08

$2.45

'

'

'

'

'

'

'

'

Stock-based compensation expense

$247,000

$172,000

$782,000

$735,000

$0

$0

'

'

'

'

'

'

Income tax benefit

'

'

0

0

'

'

'

'

'

'

'

'

Total unrecognized compensation costs

$2,100,000

'

$2,100,000

'

'

'

$1,000,000

'

'

'

'

'

Weighted-average remaining period for recognition of unrecognized compensation costs

'

'

'1 year 3 months 18 days

'

'

'

'

'

'

'

'

'

StockBased_Compensation_Schedu

Stock-Based Compensation - Schedule of Assumptions used for Estimating Fair Value of Each Option Award on Date of Grant using Black-Scholes Valuation Model (Detail) (Stock Options [Member])	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Expected volatility	'	36.00%	'	36.00%
Expected volatility, minimum	'	'	33.00%	'
Expected volatility, maximum	'	'	35.00%	'
Expected dividends	'	'	'	'
Expected life (in years)	'	'6 years 3 months 18 days	'	'
Risk-free interest rate	'	1.70%	'	'
Risk-free interest rate, minimum	'	'	1.50%	0.70%
Risk-free interest rate, maximum	'	'	1.90%	1.70%
Minimum [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Expected life (in years)	'	'	'5 years 6 months	'5 years 6 months
Maximum [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Expected life (in years)	'	'	'6 years 3 months 18 days	'6 years 3 months 18 days

StockBased_Compensation_Schedu1

Stock-Based Compensation - Schedule of Option Activity (Detail) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Stock Options [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options Outstanding, beginning balance	3,858,462	'
Options granted	74,664	'
Options cancelled	-28,452	'
Options exercised	-6,237	'
Options forfeited or expired	-38,880	'
Options Outstanding, ending balance	3,859,557	3,858,462
Vested and expected to vest	3,417,442	'
Exercisable	2,363,695	'
Options Outstanding, beginning balance, Weighted Average Exercise Price	$4.89	'
Options granted, Weighted Average Exercise Price	$5.98	'
Options cancelled, Weighted Average Exercise Price	$4.88	'
Options exercised, Weighted Average Exercise Price	$2	'
Options forfeited or expired, Weighted Average Exercise Price	$7.29	'
Options Outstanding, ending balance, Weighted Average Exercise Price	$4.89	$4.89
Vested and expected to vest, Weighted Average Exercise Price	$4.64	'
Exercisable, Weighted Average Exercise Price	$3.58	'
Options Outstanding, Weighted Average Remaining Contractual Term	'6 years 2 months 12 days	'6 years 10 months 24 days
Vested and expected to vest, Weighted Average Remaining Contractual Term	'5 years 10 months 24 days	'
Exercisable, Weighted Average Remaining Contractual Term	'4 years 8 months 12 days	'
Options Outstanding, Aggregate Intrinsic Value	$3,979,000	$6,777,000
Vested and expected to vest, Aggregate Intrinsic Value	3,979,000	'
Exercisable, Aggregate Intrinsic Value	$3,979,000	'
Time Based Stock Options [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options Outstanding, beginning balance	2,761,037	'
Options granted	74,664	'
Options cancelled	-21,500	'
Options exercised	-4,500	'
Options forfeited or expired	-31,000	'
Options Outstanding, ending balance	2,778,701	'
Vested and expected to vest	2,715,687	'
Exercisable	1,815,393	'
Performance Based Stock Options [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options Outstanding, beginning balance	1,097,425	'
Options cancelled	-6,952	'
Options exercised	-1,737	'
Options forfeited or expired	-7,880	'
Options Outstanding, ending balance	1,080,856	'
Vested and expected to vest	701,755	'
Exercisable	548,302	'

StockBased_Compensation_Schedu2

Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Recognized (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Total stock-based compensation expense	$247	$172	$782	$735
Cost of Goods Sold [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Total stock-based compensation expense	32	26	104	56
Sales and Marketing [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Total stock-based compensation expense	34	46	116	86
General and Administrative [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Total stock-based compensation expense	151	62	474	553
Research and Development [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Total stock-based compensation expense	$30	$38	$88	$40

Other_Expense_Income_Net_Sched

Other (Expense) Income, Net - Schedule of Other (Expense) Income, Net (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Other Income and Expenses [Abstract]	'	'	'	'
Foreign currency (losses) gains	$82	($174)	($311)	($180)
Tax indemnification income	359	434	163	706
Other income	'	'	'	368
Total other income (expense), net	$441	$260	($148)	$894

Legal_Proceedings_and_Continge1

Legal Proceedings and Contingencies - Additional Information (Detail) (Claim Against Insurance Carriers to Recover Business Interruption Losses [Member])	0 Months Ended
	Dec. 16, 2010
	Lawsuits
Claim Against Insurance Carriers to Recover Business Interruption Losses [Member]	'
Gain Contingencies [Line Items]	'
Number of suits filed	1

Related_Party_Transactions_Add

Related Party Transactions - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Related Party Transaction [Line Items]	'	'	'	'	'
Purchases included in accounts payable and accrued expenses	$15,383,000	'	$15,383,000	'	$18,103,000
Due from related party, accounts receivable, net	'	'	'	'	'
INC [Member]	'	'	'	'	'
Related Party Transaction [Line Items]	'	'	'	'	'
Due from parent	0	'	0	'	0
Costs incurred associated with agreement	0	0	0	500,000	'
Agreement term	'5 years	'	'	'	'
LMI [Member]	'	'	'	'	'
Related Party Transaction [Line Items]	'	'	'	'	'
Due from parent	3,600,000	'	3,600,000	'	1,300,000
VWR [Member]	'	'	'	'	'
Related Party Transaction [Line Items]	'	'	'	'	'
Expected payment to related party	100,000	100,000	200,000	200,000	'
Purchases included in accounts payable and accrued expenses	20,000	'	20,000	'	1,000
Marsh [Member]	'	'	'	'	'
Related Party Transaction [Line Items]	'	'	'	'	'
Expected payment to related party	'	'	300,000	'	'
Prepaid expense due to related party	43,000	'	43,000	'	43,000
Officer [Member]	'	'	'	'	'
Related Party Transaction [Line Items]	'	'	'	'	'
Due from related party, accounts receivable, net	'	'	'	'	100,000
Avista [Member] | Advisory Services and Monitoring Agreement [Member]	'	'	'	'	'
Related Party Transaction [Line Items]	'	'	'	'	'
Annual fee required to be paid	1,000,000	'	1,000,000	'	'
Costs incurred associated with agreement	300,000	300,000	800,000	800,000	'
Purchases included in accrued expenses	$16,000	'	$16,000	'	$30,000
Agreement term	'7 years	'	'	'	'

Segment_Information_Additional

Segment Information - Additional Information (Detail)	9 Months Ended	3 Months Ended		9 Months Ended			12 Months Ended
	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Dec. 31, 2013
	Segment	U.S. [Member]	U.S. [Member]	U.S. [Member]	U.S. [Member]	U.S. [Member]	U.S. [Member]
		Consolidated Revenues [Member]	Consolidated Revenues [Member]	Consolidated Revenues [Member]	Consolidated Revenues [Member]	Consolidated Assets [Member]	Consolidated Assets [Member]
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'
Number of operating segments	2	'	'	'	'	'	'
Concentration risk percentage	'	78.50%	73.90%	77.80%	74.80%	90.10%	89.80%

Segment_Information_Schedule_o

Segment Information - Schedule of Selected Information for Each Business Segment (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Revenues	'	'	'	'	'
Revenues	$75,682	$70,385	$224,631	$212,004	'
Operating income (loss)	'	'	'	'	'
Operating income (loss)	11,540	-4,568	30,009	-17,680	'
Interest expense, net	-10,585	-11,035	-31,704	-32,323	'
Other income (expense), net	441	260	-148	894	'
Income (loss) before income taxes	1,396	-15,343	-1,843	-49,109	'
Total Assets	'	'	'	'	'
Total Assets	258,054	'	258,054	'	259,385
U.S. [Member]	'	'	'	'	'
Revenues	'	'	'	'	'
Revenues	59,429	52,004	174,808	158,490	'
Total Assets	'	'	'	'	'
Total Assets	232,491	'	232,491	'	232,973
International [Member]	'	'	'	'	'
Revenues	'	'	'	'	'
Revenues	16,253	18,381	49,823	53,514	'
Total Assets	'	'	'	'	'
Total Assets	25,563	'	25,563	'	26,412
Operating Segments [Member]	'	'	'	'	'
Revenues	'	'	'	'	'
Revenues	80,564	74,788	238,502	227,681	'
Operating income (loss)	'	'	'	'	'
Operating income (loss)	11,502	-5,170	29,583	-17,501	'
Operating Segments [Member] | U.S. [Member]	'	'	'	'	'
Revenues	'	'	'	'	'
Revenues	64,311	56,407	188,679	174,167	'
Operating income (loss)	'	'	'	'	'
Operating income (loss)	10,493	-5,116	25,930	-18,414	'
Operating Segments [Member] | International [Member]	'	'	'	'	'
Revenues	'	'	'	'	'
Revenues	16,253	18,381	49,823	53,514	'
Operating income (loss)	'	'	'	'	'
Operating income (loss)	1,009	-54	3,653	913	'
Inter-Segment [Member]	'	'	'	'	'
Revenues	'	'	'	'	'
Revenues	-4,882	-4,403	-13,871	-15,677	'
Operating income (loss)	'	'	'	'	'
Operating income (loss)	$38	$602	$426	($179)	'

Guarantor_Financial_Informatio2

Guarantor Financial Information - Additional Information (Detail) (Guarantor Subsidiary [Member])	9 Months Ended
	Sep. 30, 2014
	Subsidiaries
Guarantor Subsidiary [Member]	'
Condensed Financial Statements, Captions [Line Items]	'
Number of guarantor subsidiaries	1

Guarantor_Financial_Informatio3

Guarantor Financial Information - Schedule of Condensed Consolidating Balance Sheet Information (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets	'	'	'	'
Cash and cash equivalents	$25,205	$16,669	$20,862	$31,595
Accounts receivable, net	41,160	38,910	'	'
Intercompany accounts receivable	'	'	'	'
Inventory	16,425	18,310	'	'
Income tax receivable	448	325	'	'
Deferred tax assets	12	18	'	'
Other current assets	4,181	3,087	'	'
Total current assets	87,431	77,319	'	'
Property, plant and equipment, net	96,072	97,653	'	'
Capitalized software development costs, net	1,829	1,470	'	'
Intangibles, net	29,203	34,998	'	'
Goodwill	15,714	15,714	'	'
Deferred financing costs	7,969	9,639	'	'
Deferred tax assets	45	15	'	'
Investment in subsidiaries	'	'	'	'
Intercompany note receivable	'	'	'	'
Other long-term assets	19,791	22,577	'	'
Total assets	258,054	259,385	'	'
Current liabilities	'	'	'	'
Line of credit	8,000	8,000	'	'
Accounts payable	15,383	18,103	'	'
Intercompany accounts payable	'	'	'	'
Accrued expenses and other liabilities	35,088	25,492	'	'
Deferred tax liability	57	57	'	'
Deferred revenue	1,063	3,979	'	'
Total current liabilities	59,591	55,631	'	'
Asset retirement obligations	7,244	6,385	'	'
Long-term debt, net	399,220	399,037	'	'
Intercompany note payable	'	'	'	'
Deferred tax liability	8	12	'	'
Other long-term liabilities	32,407	35,408	'	'
Total liabilities	498,470	496,473	'	'
(Deficit) equity	-240,416	-237,088	'	-174,353
Total liabilities and stockholder's deficit	258,054	259,385	'	'
Reportable Entities [Member] | Lantheus Intermediate [Member]	'	'	'	'
Current assets	'	'	'	'
Cash and cash equivalents	'	'	'	'
Accounts receivable, net	'	'	'	'
Intercompany accounts receivable	'	'	'	'
Inventory	'	'	'	'
Income tax receivable	'	'	'	'
Deferred tax assets	'	'	'	'
Other current assets	'	'	'	'
Total current assets	'	'	'	'
Property, plant and equipment, net	'	'	'	'
Capitalized software development costs, net	'	'	'	'
Intangibles, net	'	'	'	'
Goodwill	'	'	'	'
Deferred financing costs	'	'	'	'
Deferred tax assets	'	'	'	'
Investment in subsidiaries	-240,416	-237,088	'	'
Intercompany note receivable	'	'	'	'
Other long-term assets	'	'	'	'
Total assets	-240,416	-237,088	'	'
Current liabilities	'	'	'	'
Line of credit	'	'	'	'
Accounts payable	'	'	'	'
Intercompany accounts payable	'	'	'	'
Accrued expenses and other liabilities	'	'	'	'
Deferred tax liability	'	'	'	'
Deferred revenue	'	'	'	'
Total current liabilities	'	'	'	'
Asset retirement obligations	'	'	'	'
Long-term debt, net	'	'	'	'
Intercompany note payable	'	'	'	'
Deferred tax liability	'	'	'	'
Other long-term liabilities	'	'	'	'
Total liabilities	'	'	'	'
(Deficit) equity	-240,416	-237,088	'	'
Total liabilities and stockholder's deficit	-240,416	-237,088	'	'
Reportable Entities [Member] | LMI [Member]	'	'	'	'
Current assets	'	'	'	'
Cash and cash equivalents	20,121	11,995	13,132	17,635
Accounts receivable, net	30,611	28,099	'	'
Intercompany accounts receivable	2,962	2,671	'	'
Inventory	13,500	15,414	'	'
Income tax receivable	423	297	'	'
Deferred tax assets	'	'	'	'
Other current assets	3,916	2,906	'	'
Total current assets	71,533	61,382	'	'
Property, plant and equipment, net	75,510	76,068	'	'
Capitalized software development costs, net	1,828	1,468	'	'
Intangibles, net	26,628	31,838	'	'
Goodwill	15,714	15,714	'	'
Deferred financing costs	7,969	9,639	'	'
Deferred tax assets	'	'	'	'
Investment in subsidiaries	39,293	40,289	'	'
Intercompany note receivable	'	'	'	'
Other long-term assets	19,591	22,370	'	'
Total assets	258,066	258,768	'	'
Current liabilities	'	'	'	'
Line of credit	8,000	8,000	'	'
Accounts payable	13,810	16,672	'	'
Intercompany accounts payable	'	'	'	'
Accrued expenses and other liabilities	31,944	21,409	'	'
Deferred tax liability	'	'	'	'
Deferred revenue	1,063	3,979	'	'
Total current liabilities	54,817	50,060	'	'
Asset retirement obligations	7,049	6,212	'	'
Long-term debt, net	399,220	399,037	'	'
Intercompany note payable	5,568	5,396	'	'
Deferred tax liability	'	'	'	'
Other long-term liabilities	31,828	35,151	'	'
Total liabilities	498,482	495,856	'	'
(Deficit) equity	-240,416	-237,088	'	'
Total liabilities and stockholder's deficit	258,066	258,768	'	'
Reportable Entities [Member] | Guarantor Subsidiary [Member]	'	'	'	'
Current assets	'	'	'	'
Cash and cash equivalents	'	'	'	'
Accounts receivable, net	'	'	'	'
Intercompany accounts receivable	'	'	'	'
Inventory	'	'	'	'
Income tax receivable	'	'	'	'
Deferred tax assets	'	'	'	'
Other current assets	'	'	'	'
Total current assets	'	'	'	'
Property, plant and equipment, net	15,555	15,615	'	'
Capitalized software development costs, net	'	'	'	'
Intangibles, net	'	'	'	'
Goodwill	'	'	'	'
Deferred financing costs	'	'	'	'
Deferred tax assets	'	'	'	'
Investment in subsidiaries	'	'	'	'
Intercompany note receivable	'	'	'	'
Other long-term assets	'	'	'	'
Total assets	15,555	15,615	'	'
Current liabilities	'	'	'	'
Line of credit	'	'	'	'
Accounts payable	'	'	'	'
Intercompany accounts payable	'	'	'	'
Accrued expenses and other liabilities	'	'	'	'
Deferred tax liability	'	'	'	'
Deferred revenue	'	'	'	'
Total current liabilities	'	'	'	'
Asset retirement obligations	'	'	'	'
Long-term debt, net	'	'	'	'
Intercompany note payable	'	'	'	'
Deferred tax liability	'	'	'	'
Other long-term liabilities	'	'	'	'
Total liabilities	'	'	'	'
(Deficit) equity	15,555	15,615	'	'
Total liabilities and stockholder's deficit	15,555	15,615	'	'
Reportable Entities [Member] | Non-Guarantor Subsidiaries [Member]	'	'	'	'
Current assets	'	'	'	'
Cash and cash equivalents	5,084	4,674	7,730	13,960
Accounts receivable, net	10,549	10,811	'	'
Intercompany accounts receivable	'	'	'	'
Inventory	2,925	2,896	'	'
Income tax receivable	25	28	'	'
Deferred tax assets	12	18	'	'
Other current assets	265	181	'	'
Total current assets	18,860	18,608	'	'
Property, plant and equipment, net	5,007	5,970	'	'
Capitalized software development costs, net	1	2	'	'
Intangibles, net	2,575	3,160	'	'
Goodwill	'	'	'	'
Deferred financing costs	'	'	'	'
Deferred tax assets	45	15	'	'
Investment in subsidiaries	'	'	'	'
Intercompany note receivable	5,568	5,396	'	'
Other long-term assets	200	207	'	'
Total assets	32,256	33,358	'	'
Current liabilities	'	'	'	'
Line of credit	'	'	'	'
Accounts payable	1,573	1,431	'	'
Intercompany accounts payable	2,962	2,671	'	'
Accrued expenses and other liabilities	3,144	4,083	'	'
Deferred tax liability	57	57	'	'
Deferred revenue	'	'	'	'
Total current liabilities	7,736	8,242	'	'
Asset retirement obligations	195	173	'	'
Long-term debt, net	'	'	'	'
Intercompany note payable	'	'	'	'
Deferred tax liability	8	12	'	'
Other long-term liabilities	579	257	'	'
Total liabilities	8,518	8,684	'	'
(Deficit) equity	23,738	24,674	'	'
Total liabilities and stockholder's deficit	32,256	33,358	'	'
Eliminations [Member]	'	'	'	'
Current assets	'	'	'	'
Cash and cash equivalents	'	'	'	'
Accounts receivable, net	'	'	'	'
Intercompany accounts receivable	-2,962	-2,671	'	'
Inventory	'	'	'	'
Income tax receivable	'	'	'	'
Deferred tax assets	'	'	'	'
Other current assets	'	'	'	'
Total current assets	-2,962	-2,671	'	'
Property, plant and equipment, net	'	'	'	'
Capitalized software development costs, net	'	'	'	'
Intangibles, net	'	'	'	'
Goodwill	'	'	'	'
Deferred financing costs	'	'	'	'
Deferred tax assets	'	'	'	'
Investment in subsidiaries	201,123	196,799	'	'
Intercompany note receivable	-5,568	-5,396	'	'
Other long-term assets	'	'	'	'
Total assets	192,593	188,732	'	'
Current liabilities	'	'	'	'
Line of credit	'	'	'	'
Accounts payable	'	'	'	'
Intercompany accounts payable	-2,962	-2,671	'	'
Accrued expenses and other liabilities	'	'	'	'
Deferred tax liability	'	'	'	'
Deferred revenue	'	'	'	'
Total current liabilities	-2,962	-2,671	'	'
Asset retirement obligations	'	'	'	'
Long-term debt, net	'	'	'	'
Intercompany note payable	-5,568	-5,396	'	'
Deferred tax liability	'	'	'	'
Other long-term liabilities	'	'	'	'
Total liabilities	-8,530	-8,067	'	'
(Deficit) equity	201,123	196,799	'	'
Total liabilities and stockholder's deficit	$192,593	$188,732	'	'

Guarantor_Financial_Informatio4

Guarantor Financial Information - Schedule of Condensed Consolidating Statement of Comprehensive Income (Loss) (Detail) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Condensed Income Statements, Captions [Line Items]	'	'	'	'	'
Revenues	$75,682	$70,385	$224,631	$212,004	'
Cost of goods sold	44,044	46,664	131,873	144,524	'
Gross profit	31,638	23,721	92,758	67,480	'
Operating expenses	'	'	'	'	'
Sales and marketing expenses	8,327	8,476	27,227	27,266	'
General and administrative expenses	8,722	7,132	26,564	25,678	'
Research and development expenses	3,049	5,893	8,958	25,428	'
Impairment of land	'	6,788	'	6,788	'
Operating income (loss)	11,540	-4,568	30,009	-17,680	'
Interest expense, net	-10,585	-11,035	-31,704	-32,323	'
Other income (expense), net	441	260	-148	894	'
Equity in earnings (losses) of affiliates	'	'	'	'	'
Income (loss) before income taxes	1,396	-15,343	-1,843	-49,109	'
(Benefit) provision for income taxes	-56	-279	-374	267	'
Net income (loss)	1,452	-15,064	-1,469	-49,376	-61,678
Foreign currency translation	-671	417	-339	-1,176	'
Equity in other comprehensive income (loss) of subsidiaries	'	'	'	'	'
Total comprehensive income (loss)	781	-14,647	-1,808	-50,552	'
Reportable Entities [Member] | Lantheus Intermediate [Member]	'	'	'	'	'
Condensed Income Statements, Captions [Line Items]	'	'	'	'	'
Revenues	'	'	'	'	'
Cost of goods sold	'	'	'	'	'
Gross profit	'	'	'	'	'
Operating expenses	'	'	'	'	'
Sales and marketing expenses	'	'	'	'	'
General and administrative expenses	'	'	'	'	'
Research and development expenses	'	'	'	'	'
Impairment of land	'	'	'	'	'
Operating income (loss)	'	'	'	'	'
Interest expense, net	'	'	'	'	'
Other income (expense), net	'	'	'	'	'
Equity in earnings (losses) of affiliates	1,452	-15,064	-1,469	-49,376	'
Income (loss) before income taxes	1,452	-15,064	-1,469	-49,376	'
(Benefit) provision for income taxes	'	'	'	'	'
Net income (loss)	1,452	-15,064	-1,469	-49,376	'
Foreign currency translation	'	'	'	'	'
Equity in other comprehensive income (loss) of subsidiaries	-671	417	-339	-1,176	'
Total comprehensive income (loss)	781	-14,647	-1,808	-50,552	'
Reportable Entities [Member] | LMI [Member]	'	'	'	'	'
Condensed Income Statements, Captions [Line Items]	'	'	'	'	'
Revenues	66,927	59,416	196,435	180,453	'
Cost of goods sold	36,243	35,859	108,111	115,962	'
Gross profit	30,684	23,557	88,324	64,491	'
Operating expenses	'	'	'	'	'
Sales and marketing expenses	7,462	7,641	24,466	24,564	'
General and administrative expenses	8,222	6,585	24,822	23,844	'
Research and development expenses	2,953	5,779	8,656	25,200	'
Impairment of land	'	'	'	'	'
Operating income (loss)	12,047	3,552	30,380	-9,117	'
Interest expense, net	-10,649	-11,083	-31,896	-32,458	'
Other income (expense), net	305	409	80	1,039	'
Equity in earnings (losses) of affiliates	-497	-8,197	-657	-8,552	'
Income (loss) before income taxes	1,206	-15,319	-2,093	-49,088	'
(Benefit) provision for income taxes	-246	-255	-624	288	'
Net income (loss)	1,452	-15,064	-1,469	-49,376	'
Foreign currency translation	'	'	'	'	'
Equity in other comprehensive income (loss) of subsidiaries	-671	417	-339	-1,176	'
Total comprehensive income (loss)	781	-14,647	-1,808	-50,552	'
Reportable Entities [Member] | Guarantor Subsidiary [Member]	'	'	'	'	'
Condensed Income Statements, Captions [Line Items]	'	'	'	'	'
Revenues	'	'	'	'	'
Cost of goods sold	'	'	'	'	'
Gross profit	'	'	'	'	'
Operating expenses	'	'	'	'	'
Sales and marketing expenses	'	'	'	'	'
General and administrative expenses	20	20	60	60	'
Research and development expenses	'	'	'	'	'
Impairment of land	'	6,788	'	6,788	'
Operating income (loss)	-20	-6,808	-60	-6,848	'
Interest expense, net	'	'	'	'	'
Other income (expense), net	'	'	'	'	'
Equity in earnings (losses) of affiliates	'	'	'	'	'
Income (loss) before income taxes	-20	-6,808	-60	-6,848	'
(Benefit) provision for income taxes	'	'	'	'	'
Net income (loss)	-20	-6,808	-60	-6,848	'
Foreign currency translation	'	'	'	'	'
Equity in other comprehensive income (loss) of subsidiaries	'	'	'	'	'
Total comprehensive income (loss)	-20	-6,808	-60	-6,848	'
Reportable Entities [Member] | Non-Guarantor Subsidiaries [Member]	'	'	'	'	'
Condensed Income Statements, Captions [Line Items]	'	'	'	'	'
Revenues	13,637	15,372	42,067	47,228	'
Cost of goods sold	12,683	15,208	37,633	44,239	'
Gross profit	954	164	4,434	2,989	'
Operating expenses	'	'	'	'	'
Sales and marketing expenses	865	835	2,761	2,702	'
General and administrative expenses	480	527	1,682	1,774	'
Research and development expenses	96	114	302	228	'
Impairment of land	'	'	'	'	'
Operating income (loss)	-487	-1,312	-311	-1,715	'
Interest expense, net	64	48	192	135	'
Other income (expense), net	136	-149	-228	-145	'
Equity in earnings (losses) of affiliates	'	'	'	'	'
Income (loss) before income taxes	-287	-1,413	-347	-1,725	'
(Benefit) provision for income taxes	190	-24	250	-21	'
Net income (loss)	-477	-1,389	-597	-1,704	'
Foreign currency translation	-671	417	-339	-1,176	'
Equity in other comprehensive income (loss) of subsidiaries	'	'	'	'	'
Total comprehensive income (loss)	-1,148	-972	-936	-2,880	'
Eliminations [Member]	'	'	'	'	'
Condensed Income Statements, Captions [Line Items]	'	'	'	'	'
Revenues	-4,882	-4,403	-13,871	-15,677	'
Cost of goods sold	-4,882	-4,403	-13,871	-15,677	'
Gross profit	'	'	'	'	'
Operating expenses	'	'	'	'	'
Sales and marketing expenses	'	'	'	'	'
General and administrative expenses	'	'	'	'	'
Research and development expenses	'	'	'	'	'
Impairment of land	'	'	'	'	'
Operating income (loss)	'	'	'	'	'
Interest expense, net	'	'	'	'	'
Other income (expense), net	'	'	'	'	'
Equity in earnings (losses) of affiliates	-955	23,261	2,126	57,928	'
Income (loss) before income taxes	-955	23,261	2,126	57,928	'
(Benefit) provision for income taxes	'	'	'	'	'
Net income (loss)	-955	23,261	2,126	57,928	'
Foreign currency translation	'	'	'	'	'
Equity in other comprehensive income (loss) of subsidiaries	1,342	-834	678	2,352	'
Total comprehensive income (loss)	$387	$22,427	$2,804	$60,280	'

Guarantor_Financial_Informatio5

Guarantor Financial Information - Schedule of Condensed Consolidating Cash Flow Information (Detail) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Condensed Cash Flow Statements, Captions [Line Items]	'	'
Cash provided by operating activities	$15,448	($11,822)
Cash flows from investing activities	'	'
Capital expenditures	-5,303	-3,711
Payments (to)/from subsidiary	'	'
Intercompany note	'	'
Proceeds from sale of property, plant and equipment	227	'
Proceeds from dividend	'	'
Redemption of certificate of deposit-restricted	228	'
Cash used in investing activities	-4,848	-3,711
Cash flows from financing activities	'	'
Proceeds from line of credit	5,500	8,000
Payments on line of credit	-5,500	'
Payments on note payable	-52	-1,174
Deferred financing costs	-139	-1,188
Payments (to)/from parent	-1,741	111
Intercompany note	'	'
Payment of dividend	'	'
Cash (used in) provided by financing activities	-1,932	5,749
Effect of foreign exchange rate on cash	-132	-949
Increase (decrease) in cash and cash equivalents	8,536	-10,733
Cash and cash equivalents, beginning of period	16,669	31,595
Cash and cash equivalents, end of period	25,205	20,862
Reportable Entities [Member] | Lantheus Intermediate [Member]	'	'
Condensed Cash Flow Statements, Captions [Line Items]	'	'
Cash provided by operating activities	'	'
Cash flows from investing activities	'	'
Capital expenditures	'	'
Payments (to)/from subsidiary	1,741	'
Intercompany note	'	'
Proceeds from sale of property, plant and equipment	'	'
Proceeds from dividend	'	'
Redemption of certificate of deposit-restricted	'	'
Cash used in investing activities	1,741	'
Cash flows from financing activities	'	'
Proceeds from line of credit	'	'
Payments on line of credit	'	'
Payments on note payable	'	'
Deferred financing costs	'	'
Payments (to)/from parent	-1,741	'
Intercompany note	'	'
Payment of dividend	'	'
Cash (used in) provided by financing activities	-1,741	'
Effect of foreign exchange rate on cash	'	'
Increase (decrease) in cash and cash equivalents	'	'
Cash and cash equivalents, beginning of period	'	'
Cash and cash equivalents, end of period	'	'
Reportable Entities [Member] | LMI [Member]	'	'
Condensed Cash Flow Statements, Captions [Line Items]	'	'
Cash provided by operating activities	14,614	-13,054
Cash flows from investing activities	'	'
Capital expenditures	-5,011	-3,621
Payments (to)/from subsidiary	'	'
Intercompany note	'	'
Proceeds from sale of property, plant and equipment	227	'
Proceeds from dividend	'	4,174
Redemption of certificate of deposit-restricted	228	'
Cash used in investing activities	-4,556	553
Cash flows from financing activities	'	'
Proceeds from line of credit	5,500	8,000
Payments on line of credit	-5,500	'
Payments on note payable	-52	-1,174
Deferred financing costs	-139	-1,188
Payments (to)/from parent	-1,741	111
Intercompany note	'	2,249
Payment of dividend	'	'
Cash (used in) provided by financing activities	-1,932	7,998
Effect of foreign exchange rate on cash	'	'
Increase (decrease) in cash and cash equivalents	8,126	-4,503
Cash and cash equivalents, beginning of period	11,995	17,635
Cash and cash equivalents, end of period	20,121	13,132
Reportable Entities [Member] | Guarantor Subsidiary [Member]	'	'
Condensed Cash Flow Statements, Captions [Line Items]	'	'
Cash provided by operating activities	'	'
Cash flows from investing activities	'	'
Capital expenditures	'	'
Payments (to)/from subsidiary	'	'
Intercompany note	'	'
Proceeds from sale of property, plant and equipment	'	'
Proceeds from dividend	'	'
Redemption of certificate of deposit-restricted	'	'
Cash used in investing activities	'	'
Cash flows from financing activities	'	'
Proceeds from line of credit	'	'
Payments on line of credit	'	'
Payments on note payable	'	'
Deferred financing costs	'	'
Payments (to)/from parent	'	'
Intercompany note	'	'
Payment of dividend	'	'
Cash (used in) provided by financing activities	'	'
Effect of foreign exchange rate on cash	'	'
Increase (decrease) in cash and cash equivalents	'	'
Cash and cash equivalents, beginning of period	'	'
Cash and cash equivalents, end of period	'	'
Reportable Entities [Member] | Non-Guarantor Subsidiaries [Member]	'	'
Condensed Cash Flow Statements, Captions [Line Items]	'	'
Cash provided by operating activities	834	2,970
Cash flows from investing activities	'	'
Capital expenditures	-292	-90
Payments (to)/from subsidiary	'	'
Intercompany note	'	-2,249
Proceeds from sale of property, plant and equipment	'	'
Proceeds from dividend	'	'
Redemption of certificate of deposit-restricted	'	'
Cash used in investing activities	-292	-2,339
Cash flows from financing activities	'	'
Proceeds from line of credit	'	'
Payments on line of credit	'	'
Payments on note payable	'	'
Deferred financing costs	'	'
Payments (to)/from parent	'	'
Intercompany note	'	'
Payment of dividend	'	-5,912
Cash (used in) provided by financing activities	'	-5,912
Effect of foreign exchange rate on cash	-132	-949
Increase (decrease) in cash and cash equivalents	410	-6,230
Cash and cash equivalents, beginning of period	4,674	13,960
Cash and cash equivalents, end of period	5,084	7,730
Eliminations [Member]	'	'
Condensed Cash Flow Statements, Captions [Line Items]	'	'
Cash provided by operating activities	'	-1,738
Cash flows from investing activities	'	'
Capital expenditures	'	'
Payments (to)/from subsidiary	-1,741	'
Intercompany note	'	2,249
Proceeds from sale of property, plant and equipment	'	'
Proceeds from dividend	'	-4,174
Redemption of certificate of deposit-restricted	'	'
Cash used in investing activities	-1,741	-1,925
Cash flows from financing activities	'	'
Proceeds from line of credit	'	'
Payments on line of credit	'	'
Payments on note payable	'	'
Deferred financing costs	'	'
Payments (to)/from parent	1,741	'
Intercompany note	'	-2,249
Payment of dividend	'	5,912
Cash (used in) provided by financing activities	1,741	3,663
Effect of foreign exchange rate on cash	'	'
Increase (decrease) in cash and cash equivalents	'	'
Cash and cash equivalents, beginning of period	'	'
Cash and cash equivalents, end of period	'	'